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ABSTRACT
This research study undertook to investigate and evaluate for efficacy and safety, the
herbal remedies used for treating Diabetes mellitus in northern KwaZulu-Natal. In
addition, it sought to gain knowledge and better understanding of traditional healing
systems and the medicinal use of the natural flora. During the process of assimilating
the desired information, the epidemiological and socio-economic factors which
determine the form of medicine chosen by rural people in the region, were quantified.
Both aspects of explanatory studies i.e. experimental and observational were used.
Firstly, to evaluate the safety of the two herbal remedies, laboratory animals were
given an oral dose of the herbal medicine and observed for a period of 14 days.
Efficacy was assessed by treating Streptozotocin-induced diabetic rats with the herbal
remedies and comparing their effect on blood glucose with that of a conventional
sulphonylurea. The second part of the study was observational and it involved
monitoring human subjects (patients) for twelve months, who were already taking the
herbal preparations (n=56) and comparing their prognoses with that of a group taking
conventional medicine (n=97). A third group using both types of medicine (n=42) was
included as control measure for a possible confounding factor.
Main outcome measures; Both subjective and objective measures of the perceived
health of the diabetic patients were measured, as well as the determinants of using
traditional medicine versus conventional medicine.
xvii
The battery of toxicity tests which utilises behavioural and functional observations of
the laboratory animals, yielded no signs of toxicity or abnormal behaviour. The
histopathological examination results of the sample organs from the treated rats also
revealed no signs of abnormality that could be attributed to the herbal remedies tested.
There was no sex variation recorded in the response. The first HP tested (HP-1)
demonstrated minimal hypoglycaemic effect whereas HP-2 significantly lowered the
blood glucose of the streptozotocin-induced diabetic rats by an average of 59%. This
was comparable to the conventional medicine (Glibenclamide) used in the experiment.
After 12 months of follow-up, 93 % of traditional medicine users (n=56) were
convinced that their blood sugar was controlled because of the traditional remedy they
were using. The proportion of diabetic cases who used conventional medicine were
no better off than those who used traditional medicine or vice versa. Health status
and the financial situation (income) of the respondents greatly influenced their choice
for diabetic treatment.
The herbal remedies that were investigated were non-toxic and safe for use and
internal consumption. One preparation demonstrated a significant hypoglycaemic
effect, which was comparable to the conventional allopathic medicine used in treating
Diabetes mellitus. This study should serve as a springboard to encourage more
pharmacological evaluation of herbal medicines.
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GLOSSARY
DEFINITION AND DESCRIPTION OF TERMS
ALLOPATHIC MEDICINE
This refers to medicine practised by western trained practitioners. It is sometimes
referred to as modem medicine and it functions within a scientific empirical framework.
ANIMALS




A health facility where primary health care needs of the community are rendered. In a
rural area, the health team usually consists of nursing sister(s), auxilIary staff and an
occasional visit by a medical officer.
xix
DECOCTION
The prepared medicinal plant part [leaves, chopped bark or roots etc] is boiled in water
for a certain period before use. The supematant liquid is used for treatment.
HERBAL PREPARATION
This is sometimes referred to as remedy. It is either an infusion, decoction, inhalation,
maceration or even poultice, sauna or powder of medicinal plant(s) that purportedly
has medicinal or therapeutic value. Various parts of the plant could be used in these
preparations depending on the concentration of the active ingredient
HOSPITAL
A health service point where more than primary health care is rendered. This may
include secondary level of care and sometimes tertiary. In rural health settings
however, the level of care is usually limited to secondary level.
INFUSION
Water is boiled or just heated and poured over the plant(s) [leaves, chopped bark or
roots etc] and this is allowed to stand for some time before use.
xx
MEDICAL PRACTITIONERS
Doctors, nurses, paramedics and all providers authorized by law to provide biomedical




There are four different types of healers; the sangoma, a herbalist, a faith healer and
traditional birth attendants. In this study the term traditional healer refers to one who
uses medicinal plants in treating ailments. He/she is sometimes referred to as
traditional practitioner.
TRADITIONAL MEDICINE
These are healing systems practised by indigenous people based on African cosmology
and sometimes include supernatural or involve performing certain rituals in addition to
ingested medicine. It is founded on personal experience and observations handed
down from generation to generation, either verbally or sometimes in writing, and is
xxi
used for the diagnosis, prevention or elimination of imbalances in physical, mental or
social well-being.
TRADITIONAL PRACTICE (also TRADITIONAL MEDICINE)
This practice involves the use of traditional methods of healing, the medicine, the
rituals accompanying the administration of this medicine and the whole approach of
treating not only the patient but the including the families and the communities.
TRADITIONAL PRACTITIONER (also see TRADITIONAL HEALER)
He/she provide or use traditional methods in treatment of ailments. Traditional birth
attendants, herbalists and diviners fall under this category. There are different classes
of practices such as general practitioner and specialists who specialises on certain
ailments e.g. Diabetes specialists or STD specialists etc.
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CHAPTER 1
1.1. INTRODUCTION AND BACKGROUND
Diabetes mellitus is a metabolic disorder, and a complex chronic disease that has
become a leading cause of loss of lower limbs through amputation, renal failure
and blindness. The prevalence of Diabetes mellitus has been found to be 8% in
South Africa [Levitt et aI, 1993 Harris et aI, 1987; WHO Expert Comm, 1980]
which exceeds the recent rate of 1% recorded in Tanzania (0.8% in rural
community before age adjustment) [McLarty et aI, 1989; 1990]. In a recent
study published by Charlton and co-workers (1997), the prevalance of Diabetes
mellitus among the South African Coloured population was found to be 28.7%
(95% Cl of 21.7-35.7%). This was further classified as 25.7% in men and 30.3%
in women. Worldwide, prevalences have been found to be up to 40% [Levitt N
et aI, 1993; Reubi et aI, 1985; Harris et aI, 1987; Winegard et al 1990]. In New
Zealand, the prevalence was found to be 1.8% with no sex variation observed
[Baker et aI, 1993]. This means that South Africa has a higher prevalence rate
compared to other countries where such studies have been conducted.
Modem medicine does not cure diabetes, but provides symptomatic relief
[Goodman & Gilman, 1990; Anokute, 1990; Clarke & Campbell, 1975].
With recent developments in pharmacology and other technologies providing
the basis for evaluation,'?,~nd exploitation of natural resources, it is logical
for scientists to continue the search for a cure for diabetes. Many studies, in
different parts of the world, have demonstrated the hypoglycaemic effect of
certain medicinal plants [Meir & Yaniv, 1985; Leatherdale et aI, 1981; Keder
et al ,1982; Ibanez-Camacho et aI, 1983; Kato & Muira, 1994; Sanchez de
Medina et aI, 1994; Guntai, 1989; Vad, 1960; Ghannam et aI, 1986;
Glombitza et aI, 1994; Ajabnoor, 1990; Frati-Munari et aI, 1988; Ajgaonkar,
1979; Day & Bailey,1988; Akthar & Alli, 1995; Bailey and Flatt, 1985].
1.2. Indigenous Healing Systems
In the developing countries, the traditional method of health care delivery is
mostly based on the use of plant preparations, and this will no doubt continue to
predominate as long as most of the population remains rural. It is worth noting
that this is not just based on cost benefit analysis, but it is interwoven with the
overall beliefs and cultural ways of a rural life [Gumede,1990; Hedberg and
Staugard, 1989; Matte, 1989; Farrand, 1980; Mkhize, 1981; Wessels, 1985;
Freeman, 1990; Yangni-Angate, 1991]. The scent, taste, appearance etc, of the
plant preparations, and the rituals that often accompany their application, all
conform to such life styles and therefore command more trust as effective agents
than modem drugs [Abebe, 1990].
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Consequently, they are sometimes selected for their religious and symbolic
values. They have great importance in an holistic view of healthcare, linking
both physical and psychological aspects of health [Akerele, 1987; Aluwihare,
1982; Zeller, 1974; Neki et aI, 1985; Young, 1983].
On the other hand, traditional medicine has provided the empirical knowledge and
has served as a precursor upon which modem medicine has laid its foundations,
since time immemorial [Abebe, 1990; Sussman, 1988; Cunningham, 1988; Pujol,
1990; Yangni-Angate, A; Schlegel, 1986; Bailey, 1989]. The World Health
Organization (WHO) recognises herbal medicine and traditional healing as a
valuable and readily available resource for primary health care and has endorsed
their safe and effective use [WHO Expert Comm, 1980; Bannerman et aI, 1983].
1.3 Western Medicine
In this day and era, people all over the world are enjoying precise and state-of-
the-art medical techniques such as laser surgeries, organ transplantations and
sophisticated microsurgery. The results are generally satisfactory health, well-
being and longer life expectancies. In other words, allopathic medicine has
undeniably made great strides in terms of development and technology.
However, at the same time, although it has managed to penetrate even the remote
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corners of the world, it is not acceptable in toto [Hedberg & Staugard, 1989;
Zempleni, 1988; Whittaker, 1985; Anyinam, 1987; Ataudo, 1985; Farrand 1984;
Freeman, 1990]. There are several reasons for this: Firstly, allopathic medicine
has brought with it numerous undesirable sequelae such as iatrogenic diseases,
allergies and hypersensitivity to certain drugs, and disability due to certain
operations [Herdberg and Staugard, 1989; Gbile, 1990; Dauskardt, 1990].
Secondly, the cost of this high technology and advanced health care as a whole
has risen so rapidly that few people can afford it [Anyinam, 1987; Farrand, 1980;
Mdluli and Msomi, 1989; Gumede, 1990]. Thirdly, highly specialised and
technical care is also highly centralised and accessibility is therefore very limited
[Farrand, 1980; Anyinam, 1987; Green and Makhubu, 1984; Mkhize, 1981].
People in the rural areas particularly, have very limited access to biomedical
institutions and clinics or biomedical practitioners in comparison with those in
urban areas. Economic, political and social realities continue to limit the reach of
biomedical health systems to all parts of the country. Overwhelming evidence
indicates that, for the well being of mankind, allopathic medicine alone cannot
cope with the demand for health care for the whole population [Hogle & Prins,
1983; Bannerman et aI, 1983; Abdool-Karim et aI, 1994; Oyeneye, 1985].
Despite the endeavours of governments and international organizations to meet
the challenge posed by World Health Organization (WHO) in 1978 at Alma Ata
with its lofty goal of "Health for all by year 2000", the failure of health services to
meet the basic health needs of the third world populations is well known. With
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the important discovery of insulin in 1921, there has since been a decline in the
use of medicinal plants for the treatment of diabetes, especially in developed
countries. Notwithstanding this discovery, there is a growing need for new
antidiabetic drugs to serve as an alternative and the medicinal flora is the logical
field for such research and exploration.
South Africa's health care system is in a transitional phase at the moment, and
obviously the new government will be reviewing and reformulating policies
regarding health care delivery. When these policies are considered, it is
important that relevant debates and available knowledge on all aspects of health
are considered, so that the new health care system may represent the interests of
the majority of the people it will serve. It is quite conceivable that in the not too
distant future, African Traditional Healing and Biomedicine will not only
contribute side by side to improve the health of the South African people, but will
also find areas for collaboration with mutual benefit and a resultant
improvement of health standards for all [Freeman, 1990; Farrand, 1980; Green




Simple herbal remedies have been used for illnesses since ancient times.
Theophrastus (circa 370-285BC) a Roman, was the first to systematically compile
a document on pharmaceutical botany - De Historia Plantarum (History of
plants) [Wheelwright, 1974]. In the first century AD, Dioscorides, a Greek
physician was the first real medical botanist whose Materia medica served as the
standard reference on the use of medicinal plants for 1500 years, until the end of
the 16th century. The new methods and concepts used by a Swiss-German
physician and herbalist, Paracelsus (1439-1541) led to the beginning of chemical
research and the development of synthetic products [Dbn. Bot. Gardens,1990;
Pujol, 1990]. He abandoned many of Galen's plant prescriptions and started the
use of minerals such as zinc and antimony in his remedies [Wheelwright, 1974].
In the industrialised countries, the use of herbal remedies has been largely
replaced by synthetic products. However, it is an open secret that even in these
affluent societies, there is renewed interest to return to more natural drugs, since
these plant products have less or no long lasting side effects [Abebe, 1990;
Bannerman et aI, 1983; Abdulkadir, 1986; WHO Expert Comm, 1980].
Nevertheless, herbal remedies from plant sources have always been the prime
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tools-of-the-trade in the fight against various forms of health problems in the
developing nations and yet, they have not been exploited to their full advantage
[Cunningham, 1990; Abebe, 1990; Jingfeng, 1987; Freeman, 1991].
Their use has been the source of controversy and scepticism in modem medical
practices because of doubts about their efficacy and safety [Pantanowitz, 1991;
Xaba-Mokoena, 1991; Richards, 1991; Ojanuga, 1981; Sherwood, 1995; Koff,
1995]. This is because most of the claims have been anecdotal and have not
received adequate medical and scientific evaluation. The other reason is that the
biomedical sector has only been exposed to the failures of traditional medicine
(overdoses, enemas in childhood diarrhoea, etc) whereas the successes are left
undocumented [Abdool Karim et aI, 1994; Gumede, 1990].
Hogle & Prins (1991) estimated that the African population was 518000000 in
1983. There are approximately 1 million Traditional Healers on the continent.
This means that the Traditional Healer/population ratio is 1:500 the
doctor/population ratio is 1:40000. In KwaZulu-Natal where this study was
conducted, the doctor/population ratio is 1: 17 500 and the traditional healer/
population ratio is 1: 600 [Savage, 1985 cited in Cunningham. 1988]. This
means that the Traditional Healers are ubiquitous, and therefore readily available
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and accessible to the people, to be utilised for health care delivery [Anyinam,
1987].
2.1.1 The quest for new discovery through research
Again, spearheaded by WHO, both developing and developed countries alike, are
encouraging and promoting the use of alternative or complementary medicine, be
it Chinese Traditional medicine, Unani medicine, Ayurvedic or African
Traditional healing. In South Africa, in a similar fashion as in the rest of Africa,
Traditional healing, which existed long before biomedicine was introduced,
remains a thriving and dynamic cultural feature [Neki et aI, 1985; Hutchings et
aI, 1994; Hedberg and Staugard, 1989; Pujol, 1990; Gumede, 1990]. There is no
doubt that African Traditional healers and Traditional medicine will continue to
be utilised and this fact cannot be wished away or legislated away. South Africa
also has rich flora with many species, some of which contain active principles that
are utilised in useful remedies [Cunningham, 1988; 1990; Fourie et aI, 1992;
Hutchings et aI, 1994; Gumede, 1990]. There is a great need to protect our flora
whereby overutilisation and exploitation would be avoided and at the same time,
optimising the potential benefits that could be derived from it.
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There may be modem drugs to cure many diseases, but they are either inaccessible
or too expensive for the consumer in the developing world [Gbile, 1990; Abebe,
1990; Hackland, 1987; Maclean, 1982]. Hence the use of plant preparations by
approximately 80% of the population [Abdool Karim et al,1994; Gumede, 1990;
Bannerman et aI, 1983]. The figures (of this patronage) are comparatively more
or less the same for South Africa as for all Sub-Saharan countries. Within the
limits of our scientific resources and in view of the pressing health problems, it
justly suffices to evaluate some of the widely applied plants to determine their
activity and safety in order to render them usable and acceptable in a conventional
health care delivery system, particularly at the primary health care level. The
Chinese, though not unique in the use of medicinal plants, have shown how to
maximise health care coverage by gradually integrating the traditional with
modem medicine, and they have discovered over 60 new drugs in the last 37 years
from their local medicinal plants [Ho et aI, 1983]. In Taiwan alone, there are
more than three thousand licenced Doctors of Herbal medicine today [Pujol,
1990], whereby traditional medicine is dispensed alongside allopathic medicine.
Studies conducted by Noristan Ethnobotany Research in the late 80's and early
90's suggest that the majority of plants used in traditional medicine in Southern
Africa do indeed possess some pharmacological activity. About 31% of the
plants tested were found to be highly active therapeutically, 48% moderately
active, and 88% were found to be non-toxic [Fourie et aI, 1992].
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Renewed attention to traditional medicine and natural folk therapies have
stimulated a new wave of research interest all over the world. Numerous studies
have been documented world wide on the effectiveness of certain medicinal plants
in lowering blood glucose levels. South African scientific literature is however
lagging far behind in such evaluative studies. A few studies that have been
conducted, mostly deal with identification of medicinal and therapeutic value of
the plants but lack the comprehensive evaluation of their safety and efficacy. In
other countries research on this aspect of traditional remedies has been going on
for a long time. Most of these countries have established research centres or
departments of Traditional Medicine at universities, Health Ministry departments
or as separate institutes. In Tanzania for example, the Department of Traditional
Medicine is attached to the Ministry of Health, and they have reported on a
number of medicinal plants that have hypoglycaemic effect [Chabra et aI, 1984;
Hedberg and Staugard, 1983; Abdool Karim et aI, 1994; Bannerman etal, 1983;
Hogle & Prins, 1991]. In Japan, Hikino and co-workers have isolated and
documented several alkaloids from Japonica rhizophors that demonstrated
hypoglycaemic activity [Hikino et aI, 1986]. Similarly, numerous studies have
shown the blood glucose lowering effect of Mormodica species [Bailey et aI,
1986; Day and Bailey, 1988; Leatherdale et aI, 1981; Vad,1960; Meir et aI,
1985; Keder et aI, 1982]. Some of these studies are done on
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experimental diabetic animals, [Ibanez- Camacho et aI, 1983; Akthar & Alli,
1995; Guntai et aI, 1989; Bailey et aI, 1986; Kato & Muira, 1994; Glombitza et
aI, 1994; Sanchez de Medina et aI, 1994; Bone et aI, 1985; Ganda et aI, 1976;
Mordes,1985], whereas some have been Phase 11 clinical trials using human as
subjects [Mossa, 1985; Ajgaonkar, 1979; Frati-Munari et aI, 1988; Ghannam et
al,1986; Haller, 1990; Ajabnoor,1990]. Ghannam and his co-workers (1986)
for instance, reported the hypoglycaemic effect of aloes studied in five patients
with non-insulin-dependent diabetes, as well as in alloxan-induced-diabetes
Swiss albino mice.
There are a few studies being conducted on in South Africa, at various universities
but they are not co-ordinated. Most of them have as their ultimate goal the
establishment of: a data base of traditional medicine such as the TRAMED
project; a Traditional Medicines' Pharmacopoeia; conservation; or simply
concentrate on isolating and identifying the therapeutically active ingredients
[Hutchings, 1989; Wainwright, 1977; Savage, 1985; Croom,1983; Cawe,
1986]. Almost every university now has some form of research relating to
traditional medicine in their botany, pharmacology, anthropology, pharmacy,
botany or phytochemistry department. Even pharmaceutical companies such as
Glaxo are now seeking traditional healers assistance in identifying plants that can
be used to manufacture new drugs [Koch,1995]. There is however a dearth of
documented studies that comprehensively evaluate traditional remedies (both
11
pharmacological and epidemiological) in the treatment of Diabetes mellitus, hence
the need and relevance for the present study.
In summary, this thesis argues that traditional medicine has an important role to
play in the treatment of diabetes. However, even if the traditional medicine for
diabetes may be deemed by some to be merely a 'placebo effect' or
'psychological opium', it remains a fact that more than 80% of the sub-Saharan
population patronise it, have faith in it, and may actually derive some benefit
from it [Farrand, 1980; Mkhize, 1981; Mankazana, 1994; Simon, 1991]. This
should serve as encouragement to the scientists to continue researching all
aspects of traditional medicine.
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CHAPTER 3
3.1 THE PURPOSE· AND AIM OF THE STUDY
In spite of the remarkable advances of allopathic medicine, there is ever
increasing evidence that even where biomedical institutions are readily available
and accessible, indigenous people continue to utilise the services of African
Traditional Healers [Gumede 1990, Maclean, 1982; Wessels, 1985; Mankazana,
1994; Neuman and Lauro, 1982; Simon, 1991; Abdulkadir, 1986]. There are
numerous reasons for this and these include "inter alia" a belief that certain
diseases can only be cured by biomedical practitioners and vice versa. Chronic
diseases such as diabetes, especially, fall under this category. After taking the
same medication for extended periods with no "cure" , there is a tendency to look
for an alternative.
3.2. Definition and Classification of Diabetes mellitus
Diabetes mellitus is a chronic condition characterised by a lack of insulin
secretion and/or increased cellular resistance to insulin resulting in symptomatic
glucose intolerance and hyperglycaemia and other metabolic disturbances. The
symptoms of Diabetes mellitus include: excessive thirst and hunger, frequent
urination, weight loss, blurred vision and recurrent infections; urinary tract and
monilial infections. If this hyperglycaemia is not controlled, complications may
13
set in and these include renal, ocular, cardiovascular or severe neurological
complications. Diabetes is classified into three types; Type I which is Insulin-
dependent Diabetes mellitus (IDDM), which is sometimes called the juvenile-
onset diabetes. This affects approximately 5-10% of the diabetic population and
appears, although not always, before the age of 30 years. These patients have no
pancreatic reserve of insulin and are solely dependent on exogenous insulin to
sustain life. They have a tendency to develop ketoacidosis. The second type is
the Non-Insulin dependent Diabetes mellitus (NIDDM) or Type 11 diabetes. This
is characterised by the presence of endogenous insulin, an absence of ketosis and
the time of onset which is usually over 30 years; hence the name, adult-onset
diabetes. The third category is called the Gestational Diabetes mellitus (GDM)
since its symptoms usually appear for the first time during pregnancy. This
could be transient, disappearing soon after delivery, or sometimes show signs of
permanent disability in the disease state.
The risk factors for NIDDM include: obesity, a family history of diabetes,
hypertension, a history of GDM, sex (female being more susceptible), race
(Blacks* and Hispanics are more susceptible), degree of urbanisation, upper-
segment fat distribution and alcohol abuse [Albertse et aI, 1990; Baker et aI,
1993; Levitt et aI, 1980; Gilman and Gilman, 1990; Nesher et aI, 1987; Nutrition
SubComm., 1982; Koda-Kimble et aI, 1983].
Blacks in this case in according to the American definition.
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3.3. Diagnosis and Treatment of Diabetes mellitus
The diagnosis of diabetes comprise of glucose tests in those patients presenting
with symptoms and a standard oral glucose tolerance challenge (GGTT) in
individuals that are asymptomatic. Seventy five grams of glucose for an adult
and 1.7Sg/kg for a child is administered orally and the random venous plasma
glucose should be less than 9 mmol/l after 2 hours if the patient is normal.
However, if the patient is diabetic this random check of blood glucose should be
equal or higher than 11 mmol/l after the same period of administration. The
Nutrition sub-Committee of the British Association's Medical Advisory
Committee (1982), recommended that those patients that are borderline, sub-
clinical and asymptomatic be left untreated because the label "diabetes" has broad
social, psychological and economical impacts [Nutr sub-Comm, 1982; WHO
Expert Committee, 1980].
The therapeutic goals of treatment, once initiated, are to relieve the immediate
symptoms of diabetes (polydypsia, polyuria, weight loss, fatigue and recurrent
monilial infections) and control the blood glucose levels as well as to prevent
complications and reduce excess mortality. Many studies that have been
conducted on the treatment of diabetes suggest that tight control of
hyperglycaemic levels (to near normoglycaemia) may help retard the onset of
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complications and prevent high morbidity and mortality associated with Diabetes
mellitus [Schwartz and Clancy, 1984; Sprafka et aI, 1988; Winocour et aI, 1990;
Melander et aI, 1989; Baker et aI, 1993; Levitt et aI, 1980; Goldstein et aI, 1986;
Winegard et aI, 1990].
There are different modalities of treatment. The first line of treatment is the non-
drug modality which involves diet, exercise, reducing and controlling weight and
regular monitoring of blood pressure, glucose levels etc. If this then fails to
control blood sugar, sulphonylureas have been successfully used for decades in
treatment of NIDDM in lowering blood glucose levels by increasing (3-cells
sensitivity to glucose, to release insulin or exogenous insulin in the case of IDDM.
Extra-pancreatic effects such as, improved tissue sensitivity to insulin has been
cited as one of the mechanisms of action of some sulphonylureas [Clarke and
Campbell, 1975; Asplund et ai, 1983; Day & Bailey, 1988; Goodman and
Gilman,1990; Melander et aI, 1989]. They however, differ in their
pharmacokinetics with different plasma half-lives. Glibenclamide is one of the
second generation sulphonylureas and in recent times has become one of the most
commonly prescribed drug for NIDDM. It has been suggested that the second
generation sulphonylureas may be less susceptible than older agents to
displacement by other acidic, highly protein-bound drugs [Melander et aI, 1989;
Jackson et aI, 1981; Balant, 1981]. Sulphonylureas have no beneficial effects on
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pancreotomized individuals or Type I diabetics, hence their use is limited to
symptomatic NIDDM.
Many studies have demonstrated that the diabetic patient's knowledge and
understanding of their disease can have a tremendous positive influence on
diabetic control [Skyler,1978; Bunn,1981; Balant, 1981; Jackson et aI, 1981;
Anderson et aI, 1990; Melander et aI, 1989; Baker et aI, 1993]. This encourages
the patient to do self-monitoring which is the key to management [Anon, 1991;
Skyler, 1982; Nutr SubComm., 1990].
Claims of the effectiveness of herbal remedies are abundant but mostly anecdotal
and have not received adequate medical or scientific evaluation [Maurice and
Cream, 1989; Mac1ean & Bannerman, 1982; Ho et aI, 1984; Macgregor et aI,
1989].
The aim of this study was to determine the safety and effectiveness of some
medicinal plant preparations used for the treatment of Diabetes mellitus in the
Northern KwaZulu-Natal area as well as explore and seek more understanding of
traditional healing systems .
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Some specific research questions that this project attempted to answer include
the following:
*What are these herbal remedies? From which medicinal plants are the
constituent active ingredients derived?
*Are these herbal remedies efficacious in lowering blood glucose levels?
*If the herbal remedies are efficacious, what is the duration of their
effect or action?
*How safe are those herbal remedies for human medicinal use?
*What are the determinants of traditional medicine use?
* How beneficial is the use of traditional medicine?
To achieve these aims two different studies, a pharmacological and
epidemiological approach, were undertaken.
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3.4. Objectives
3.4.1 Objectives of the Pharmacological study
• To test the efficacy of these remedies on laboratory rats (laboratory-induced-
diabetic rats) using in vitro testing models and comparing the different
treatment modalities.
• To test the safety of these remedies by subjecting them to a battery of
toxicological tests (acute oral toxicity) using laboratory rats.
3.4.2 Objectives of the Epidemiological study
*. To obtain information and samples of the herbal remedies from the traditional
healers as well as the data on established chronic diabetic patients who use them.
This information included the preparation and formulation (parts of the plants
used and all other ingredients) and the directions for use by the patient. The
diagnosis and treatment of Diabetes mellitus was to be verified by using
hospital/clinic records.
*. To identify three groups of diabetic patients (those who use herbal remedies
only, those who use herbal remedies concurrently with allopathic medicine and
those who use allopathic medicine only) in order to assess the degree of control
achieved in the blood glucose levels.
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*. To monitor the patients over a period of one year and to compare the prognosis
in the three groups.
3.5 FEASIBILITY STUDY
A preliminary investigation was conducted prior to the actual data collection to
establish attitudes towards utilisation of indigenous medicinal plants by both the
traditional healers and their patients or the community at large.
3.5.1. Objectives:
The main objectives of this pilot run were threefold:
1. To determine the feasibility of the project as a whole. African traditional
healers are known to be secretive and keep their knowledge to themselves. The
consent and willingness of the traditional healers to participate, reveal and to
make available their remedies was therefore critical to the study.
20
2. To test questionnaires on a sample population in order to make the necessary
revision and adjustments to the questionnaires for utilisation in the main study
prior to actual data collection.
3. To assess and attempt to minimise the extent of logistic problems in tracing
patients and traditional healers in a rural setting where communication and
contacting people might be difficult. They are often without street addresses,
telephone lines and other modem technologies.
3.5.2. Methods:
Five students from University of Durban-Westville (in their second year of study
in the Science Faculty) were identified as willing fieldworkers. They were
trained by the Principal Investigator in ethnographical interviewing, sensitised to
the African traditional customs and briefed on signs, symptoms and treatment of
Diabetes mellitus. This training took two weeks and was done prior to the pilot
study.
Three meetings were held with the traditional healers; two of which were
individual interviews at Hluhluwe and Phongola and the third was a meeting with
11 traditional healers at Hlabisa. Out of the 11 traditional healers present, 5 had
and still did treat Diabetes mellitus and were then interviewed individually. Out
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of the 7 (five from Hlabisa plus the other two from Hluhluwe and Pongola), two
specialised in Diabetes mellitus and the rest were traditional general practitioners,
treating a whole variety of diseases or specialising in other areas such as
hypertension or kidney diseases etc. A standardised questionnaire was used for
these interviews (see Appendix IV) and this was then adjusted and later used for
data collection for the main study.
From these interviews, recipes and names of the plants they used in treating
diabetes were obtained. All, but one, were willing to give their formulas for
preparations or give their already prepared medicines to be used for laboratory
tests.
Overall, they all expressed keenness in collaborating in this study, even when it
was explained to them that their medicines and their practices would be
scrutinised and subjected to scientific evaluation.
3.5.3 Results:
From all 7 traditional healers, a list of the patients treated was obtained. Twenty
four of these patients could be traced, their consent sought and they were
interviewed at their homes.
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Out of the 24, seventeen used the traditional medicine concurrently with
allopathic medicine. There were 8 males and 9 females, mostly: unemployed,
homemakers or self-employed. Some of these people only kept the allopathic
medicine (especially insulin) for emergencies, when the symptoms of
hyperglycaemia occurred. They also went to the clinics only to have their blood
glucose levels checked. Seven patients believed and strictly controlled their
blood glucose levels by taking traditional medicine only. In general, all of them
felt that the traditional medicine helped them and that they had better control of
the disease due to its use. The reasons they cited for their patronage of traditional
healers varied from: difficulties in attending clinics due to distance or lack of
transportation; prohibitive costs as some were pensioners or simply unemployed;
and waiting periods at the clinics before they are attended.
A third group of patients were interviewed as they came out of the diabetic clinic
(Hlabisa hospital). These patients were later used as part of the control group for
the study. These patients used allopathic medicine only. The majority of them
were sophisticated. Distance or cost was not a problem to them and some had
medical aid schemes that absorbed most of their costs.
3.5.4 Limitations of this Study:
Most of the difficulties encountered stemmed from tracing and locating the
people; both the traditional healers and their patients. This was rendered more
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difficult by the fact that there are no street addresses or phones in the rural area.
As a result, a lot of legwork and high transportation costs were incurred. The
time spent in locating patients was more than the time spent on interviews. In
addition to time delays, financial constraints and inaccessible roads compounded
the difficulties in locating patients. The fact that most of the traditional healers
themselves do not keep good records, further complicated the matter.
The other problem related to availability of accommodation for the fieldworkers
and future studies could become relatively more expensive if fieldworkers from
outside town are brought in to collect data.
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CHAPTER 4
THE PHARMACOLOGICAL STUDY OF SELECTED TRADITIONAL
MEDICINES
4.1 BACKGROUND AND FORMULATION DESCRIPTIONS
The approval of the Ethics Committee of University of Durban-Westville was
obtained prior to the commencement of the project (see Annexure I).
Upon interviewing traditional healers, it was realised that all those who are based
in one locality or proximity, basically tend to use similar plants ( with minor
variations in excipients) in their formulation of antidiabetic remedies.
Consequently, it was considered to study the two most widely used preparations.
The premise was that the two preparations were representative of the
antidiabetic preparations used in the northern parts KwaZulu-Natal province.
The herbal preparations (HPs) were used as they were prepared and made
available by the traditional practitioners themselves. The HP contained
numerous plants and other ingredients. Individual plants were not tested for
specific activities since the combination could possibly have different effect/s
compared to a formulation with only one plant species in use; such as a
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potentiation of effect, detoxification or modification of toxic substances, or even
attenuation of therapeutic effect. Hutchings (1991), in her studies discovered that
certain species have been used and are still used to counteract the harmful effects
of others in herbal preparations made from more than one species.
4.1.1 THE FIRST HERBAL PREPARATION (HP-l)
Description
This aqueous preparation or mixture comprised of a piece of the leaf blade of Aloe
arborescens (umhlabajinhlaba or inkalane), a whole plant - from the roots to the
flower of Catharanthus roseus (isisuhlungu or ikhwinini) and the bulbus root of
Hypoxis oligitricha (ilabatheka).l These morphological parts were harvested and
boiled together for about five minutes, cooled and sieved. The "other"
ingredients that were added depended on the traditional practitioner. These were
either additional medicinal plants or minerals. One traditional healer for example
added "blue stone" and another added a sour stone called "alum". Both these
stones served as preservatives for the formulation and made the concoction last
for an extended period without promoting instability.
4.1.2. THE SECOND HERBAL PREPARATION (HP-2)
Description:
1 Botanical taxonomical classification was done concurrently with Hutchings [personal comm) and Pujol, 1990
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The second Herbal Preparation (HP-2) comprised mainly of Momordica carifolia,
or Momordica Joetida, or Momordica involucrata, (intshungu) - all three
different species were available in different sub-regions of the study site,
Cannabis sativa - dagga (insangu ) and a Musa sapientum thyrse (inhliziyo ka
Banana).2 These were also boiled together, cooled and sieved before bottling.
In this preparation, leaves were the main ingredient from all medicinal plants
except for the Musa sapientum (banana tree - Family Musaceae) whereby the
heart-shaped bud that grows in front of the bunch of fruit, was used. Some
traditional healers mixed the dagga with cow's milk. Similar to the first
preparation, several "other" undisclosed excipients were added in the formulation.
4.1.3 The Streptozotocin model for Diabetes mellitus:
The streptozotocin-induced diabetic rat represents one of the most useful tools
available to researchers in testing the effects of anti-diabetic drugs.
Streptozotocin (STZ) possess at least four major biologic properties; its
antibiotic, f3-cytotoxic, oncolytic as well as oncogenic effects. Ganda et al (1976)
who studied different models of experimentally induced diabetes, found (in their
microscopic studies) alterations in the tissues signifying these effects. These
alterations included mild beta-cell secretory degranulation, nuclear pyknosis and
cytoplasmic clumping. With STZ doses higher than 20mglkg, progressively
severe beta-cell necrosis and degranulation were observed. When a high dose of
2 Taxonomical classification and identification by Hutchings [personal communication] and references in Pujol, 1990;
Gumede, 1990.
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streptozotocin is given, irreversible dysfunction of glucose level normalising and
insulin secreting abilities is observed. Low doses of streptozocin however, in
addition to the disturbances mentioned above, also disturbs organs other than
pancreas [Kawada et aI, 1986; Ganda et aI, 1976; Jacobs et al; 1989]. The
mechanism of its diabetogenic activity has been explained by supposing that DNA
methylation is closely related to poly (ADP-ribose) synthetase in pancreatic beta-
cells. The result of this activity coupled with the beta-cell secretory
degranulation, is that insulin secretion is impaired
Portha & Serradas [1991 ] described a model of STZ-induced diabetic Wistar
rats generated by injection of newborn rats with 100mg/kg STZ. As adults these
animals exhibit decreased (about 50%) basal plasma insulin level coupled with a
deficient insulin response to glucose both in vivo and in vitro; a frank elevation of
basal plasma glucose value and impaired glucose tolerance, raised glycosylated
haemoglobins, and a marked reduction of pancreatic insulin stores. A modified
version of this model was used in this study; Wistar albino rats were injected with
65mg/kg so that the characteristics of their diabetogenicity resembled that of the
diabetic human being. These rats exhibited a failure of insulin release in





An experimental study design was used whereby two groups of rats were
assigned different treatments (the herbal preparation and a conventional
sulphonylurea) for comparison. The third group was used as a control group by
assigning it to a placebo treatment. Glibenclamide was chosen for this
experiment since in recent times it has become the most commonly prescribed
second generation oral antidiabetic drug [Melander et aI, 1989; Balant, 1981].
The exact reason of why glibenclamide has become the most popular oral
hyperglycaemic drug is not yet known [Koda-Kimble et aI, 1983; Asplund et aI,
1983].
4.2.2 Acute Oral Toxicity Test (AOTT)
The Organization for Economic Cooperation and Development (OECD)
recommended method for acute oral toxicity testing was used. The WHO
guidelines were also taken into account when these clinical trials and toxicity tests
were conducted [WHO publication, 1974; Hunter et aI, 1979; OEeD, 1977].
Acute oral toxicity is the adverse effects occurring within a short time of oral
administration of a single dose of a substance or multiple doses given within 24
hours [OECD,1977]. In the assessment and evaluation of the toxic
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characteristics of any substance, determination of acute oral toxicity is one of the
first steps and especially in this case, since the substance in question is ingested.
Thirty normal and healthy adult Wistar Albino rats ranging from 175g to 250g
were divided into three groups of 10, each group consisting of five female and
five male rats. They were acclimatised for three days prior to the experiment, in a
controlled environment of 22°C, 30-70% humidity and 12 hours of light and
dark cycles respectively. Each group was given a specific (once only) dose of the
HP by oral intubation and then observed for any behavioural changes from the
norm. Table I lists the number and types of observations that were carried out
on the animals (see Appendix I for detailed interpretation).
These observations were carried out, initially before dosing, everyday for three
days after dosing and then every second day for 14 days starting at Day 1. A
special data collecting form was used (see Annexture II). The first group was
given 0.6ml of the HP-1 (the normal dose being OAml calculated from the dose
given to human subjects and based on HP-1 mls/body wt). The second group was
given 1.2mls and the third group was given 2.0 ml respectively. After the 14th
day, the rats were euthanised and autopsied. Specimens were harvested,
preserved in 10% formalin, and used for histopathological examination. The
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organs harvested for these tests were portions of pancreas, liver, kidney and
spleen.
Ideally, a control group receiving placebo instead of an herbal preparation should
have been included in the study. However, due to financial constraints, this was
not possible. Thus, in this study, the effects of lower dose of HP were compared
with the effects of the very high dose of HP.
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TABLE 1
FUNCTIONAL/BEHAVIOURAL OBSERVATIONS CARRIED OUT
ON THE STUDY RATS
HOME CAGE HANDLING OPEN FIELD REFLEX
Clonic Lacrimation Arousal Air Righting
Convulsions Reflex
Palpebral Palpebral Bizarre Pupil Response
Closure Closure Behaviour
Tonic Salivation Clonic Object Approach
Convulsions Convulsions Response
Vocalization Vocalization Gait Score Touch Response
Posture Ease of Gait Type Click Response
Removal


















Bizarre Reaction (Jumps, Bites, Attacks)
or, Y/N where possible
See Appendix I for detailed measures
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4.2.3. Diabetic Clinical Trial
A total of 30 rats were used, divided into subgroups of 10 with each subgroup
comprising of five females and five male rats. On the eighth day after induction
of diabetes, the treatment and experimentation began. The first subgroup (X) was
treated with Glibenclamide suspension (3mg/kg body wt - a method used by
Sanchez de Medina et aI, 1994), the second (Y) with Distilled water - the control
group and the third group (Z) treated with HP-I. Food and water were available
ad libitum during the experiment and the animals were housed in well-ventilated
individual cages which were cleaned regularly.
Firstly, the glucose levels were determined and recorded using urine dipsticks and
glucometers. The weight of each animal was also recorded. The animals were
starved overnight, prior to testing. On the test day, and every second day, the
urine glucose and blood glucose levels were recorded before the treatment dose
for the day was given. The weights were measured every first day of the week.
The data was recorded on a form specially designed for this (see Annexture II).
After the tests, the animals were fed (with pellet chow) and given water ad lib.
To prevent possible injury during administration of the treatment dose; which was
done daily for a period of twenty six days (HP, Glibenclamide suspension or
distilled water) the treatment dose was mixed with a third of the daily ration of
standard food. This was devoured in 15-20 minutes. Once that was ingested, the
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rest of the daily ration was given to be taken ad lib. This dosage schedule was
similar to that of HP and Glibenclamide. The traditional healers encouraged that
their patients take half a cup every morning and if the symptoms of high sugar
level were not abating, then an additional evening dose was suggested. Similarly,
glibenclamide is prescribed as a daily dose that is increased to two daily or one
twice a day if necessary.
In all studies, blood samples were taken by tail spin and their blood glucose level
were measured by a glucometer (Glucometer Elite) using one drop of blood.
The experiment continued until the 26th day when the animals were euthanized
and organs harvested for histopathological tests. Portions of the pancreas were
homogenised in a solution of 76% ethanol, 1.5% HCl12 mmol/litre and 22.5%
distilled water for a determination of insulin content. The supernatant liquid
obtained from these samples were kept at -20°C and the insulin levels determined
by double antibody radioimmuno assay (kit by Amersham UK Ltd & Isolab Inc.)
within two months of storing these samples.
A similar procedure to 4.2.1. and 4.2.2. above was applied for the HP-2 with
group A given HP-2, group B treated with Glibenclamide suspension and group
C used as control and given Distilled water respectively.
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4.2.4. Oral Glucose Tolerance Test (OGTT)
At the end of the diabetic clinical experiment and before sacrificing the animals,
an oral glucose tolerance test was performed on the animals used at 4.2. above.
Five rats from each sub-group, two male and three females, were used for this
test. The animals were starved overnight and the test, OGTT, performed in the
morning after they had been given their daily dose of the relevant treatment (HP,
Glibenclamide or Distilled water respectively). Four hours after the treatment, a
bolus of glucose solution (0.8g/kg dissolved in 0.2mljlOg body wt of water - a
model described by Glombitza et al (1994) and WHO guidelines, was
administered by intragastric tubing. Blood glucose levels were again tested
before administration, and at 0.5, 1.0, and 2.0 hrs after administration.
4.2.5. Weight Studies
Weights of each animal in the groups studied i.e. X,Y,Z and A,B,C groups, were
recorded once a week i. e. every Monday when the experiments were conducted.




The technicians performing histopathological testing and biochemical assays (the
radioimmunoassays - RIAs), were blinded to the treatment groups of the
specimen and the type of treatment administered to the animals. The dose given
to each group was also not disclosed to the technicians and neither to the
statisticians doing the analysis. The statistical analysis used for comparing the
three groups was performed by analysis of variance (ANOVA) the Scheffe' F test
for the AOTT data, one-way analysis of variance for the diabetic trial [Gould,
1980; Kleinbaum et aI, 1988]. The test statistic (H) was computed by using the
following formula:
k R. 2
H = 12 I-J- -3(n+1)
n(n + 1) j=l nj
k
n
= the number of groups.
.th
= the number of observations in the } group.
= the number of observations in all groups combined.
.th=the sum of the ranks in the } group.
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4.3. RESULTS
4.3.1. ACUTE ORAL TOXICITY TEST RESULTS
4.3.1.1. Herbal Preparation-1
4.3.1.1.1. Mortality:
For the first group (AOTT) different dose levels (2.0ml, 1.2ml and O.6mO of the
HP-1 (groups X, Y and Z) were tested in that order. These were all above the
recommended therapeutic dose which is OAml (calculations based on ml/body wt
as given to human subjects by traditional healers). No animals died within 24
hours which is the critical period for this test. experiment. They all lived up to the
end of the experiment (14 days) when they were necropsied.
No mortality was observed in all three groups, despite the doses used which were
above the normal recommended therapeutic doses and no sex variation was
observed in the treated groups.
4.3.1.1.2. Behavioural observations:
There was no significant change in the functional or behavioural observations
with the exception of four reflex observations; the click response, the tail pinch
response, object approach response and the touch response. Even with these
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observational changes, there was minimal change from the first day of
observation to the last one, i.e. the eighth observation on the fourteenth day. The
recorded variation among the groups (i.e. different dose levels) was minimal.
This is depicted in Table IIa and lIb and Figure la and lb overleaf. The Tail
Pinch scores for example, were slightly higher than normal in all of the three
groups, which could be attributed to the fact that the animals were reacting to the
attention given to them. As they got used to this attention, their response
decreased to be slightly below normal (see Table lIb and Figure Ib). Similarly
with the Click Response scores, a minimal change was recorded.
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TABLE Ha
REFLEX OBSERVATION TEST - CLICK RESPONSE MEAN SCORES
Observation Days
I Day 1 I Day 2 I Day3 I Day 5 I Day 7 I Day 9 I Day 12
Group X 3 3 3 3 3 3 3
Group Y 3 3 2 2 3 3 3
Group Z 3 3 3 3 3 3 3
Key: 1 = No Reaction
2 = Slight Reaction
3 = Normal Reaction
4 = Increased Reaction
5 = Bizarre Reaction (Jumps, Bites, Attacks)
X =2.0ml dose group
Y = 1.2ml dose group
Z =O.6ml dose group
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5 =Bizarre reaction (Jumps, Bites, Attacks)
See Appendix I for full details on score measurements
x=2.0ml dose group
Y =1.2ml dose group
Z =O.Gml dose group
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TABLE lIb
REFLEX OBSERVATION TEST- TAIL PINCHES MEAN SCORES
Observation Days
I D~1 I D~21 D~31 D~51 D~71 Day 9 I Day 12
GROUP X 4 2 3 3 2 3 3
GROUPY 3 4 3 3 3 2 3
GROUP Z 3 3 3 3 3 3 3
Key: 1 = No Reaction
2 = Slight Reaction
3 = Normal Reaction
4 = Increased Reaction
5 = Bizarre Reaction (Jumps, Bites, Attacks)
See Appendix I for full detials on score measurements
X =2.0ml dose group
Y = 1.2ml dose group















REFLEX: TAIL PINCHES SCORES
Observations
Key: 1 =No Reaction
2 =Slight Reaction
3 =Normal Reaction
4 = Increased Reaction
5 =Bizarre Reaction (Jumps, Bites, Attacks)
X =2.0ml dose group
Y = 1.2ml dose group




The Click Response is used here as an example. Each of the behavioural
observations was assigned a score of 1 through 5. The score of 1 indicated
normality and that of 5 indicated total abnormality. In some cases, a score of 1
indicated no reaction with 5 indicating a totally bizzare and unusual reaction
(again, the full explanation is in Appendix 1). The mean scores obtained in
4.3.1.1.2 above ranged from 2.3 to 3.1. This was the score that was entered in the
analysis. A non-significant difference (p-value = 0.372) was observed between
groups and within groups (p-value = 0.294) both at the beginning and at the end
of the experiment. The following Table lIe illustrates the these results.
TABLE lIe. ANOVA RESULTS OF CLICK RESPONSE SCORE (HP-l)
SOURCE SS* di MS** V.R.*** p-Value
Among groups 1.0014 2 0.5006 5.2529 0.05>p>0.025
Within groups 1.7143 18 0.0953
TOTAL 2.7157 20
*SS = Sum of Squares, **MS=Mean squares, *** V.R. = variance ratio
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4.3.1.1.4. Histopathological Results
No abnormal lesions were detected by the histopathologists (see Appendix II for
detailed report). The minor morphological changes detected were symptoms of
the onset of chronic nephropathy, which is consistent and is a known
characteristic of the laboratory animals used. The difference in the doses did not
produce any difference in the histopathological examination. The results of acute
oral toxicity studies of HP-l indicate that it is non-toxic to rats..
4.3.1.2. Herbal Preparation-2
Similar to the first groups (X, Y and Z); 0.6, 1.2 and 2.0ml were the doses used in
group A, Band e, respectively, in testing acute oral toxicity of HP-2.
4.3.1.2.1 Mortality:
No mortality was recorded within the critical period of the first 24 hours and
none of the animals died until they were euthanized after 14 days of observation.
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4.3.1.2.2. Behavioural Observations:
Similar to the HP-l groups, there was minimal change (from normality) from the
first observation to the last day, as well as the variation among the three groups
(with three different dose levels) was minimal. The Click Response and Tail
Pinch response were chosen as an example also in HP-2 to provide consistency in
the comparison. Table IlIa and IIIb and Figure 2a and 2b depicts the results of




REFLEX OBSERVATION TEST- CLICK RESPONSE MEAN SCORES
Observation Days
I Day 1 I Day 2 I Day 3 I Day 5 I Day 7 I Day 9 I Day 12 I Day 14
GROUPS A 2 3 3 3 3 3 3 3
GROUPSB 2 3 3 3 3 3 3 3
GROUPSC 3 3 3 3 3 3 3 3
Key: 1 = No Reaction
2 = Slight Reaction
3 = Normal Reaction
4 = Increased Reaction
5 = Bizarre Reaction (Jumps, Bites, Attacks)
A= O.Gml dose group
B= 1.2ml dose group















REFLEX - CLICK RESPONSE CURVES
Observations




5 =Bizarre Reaction (Jumps, Bites, Attacks)
A =O.Gml dose group
B =1.2ml dose group




REFLEX OBSERVATION TEST - TAIL PINCH RESPONSE (MEAN SCORES)
Observation Days
I Day 1 I Day 2 I Day 3 I Day 5 I Day 7 I Day 9 I Day 12 I Day 14
GROUPS A 3 4 3 3 3 3 3 3
GROUPSB 3 3 3 3 3 4 3 3
GROUPSC 3 3 3 3 3 4 3 3
Key: 1 = No Reaction
2 = Slight Reaction
3 = Normal Reaction
4 = Increased Reaction
5 = Bizarre Reaction (Jumps, Bites, Attacks)
See Appendix I for details on score measurements
A =O.6rnl dose group
B =1.2ml dose group














REFLEX - TAIL PINCH RESPONSE
Observations




5 = Bizarre Reaction (Jumps, Bites, Attacks)
A =O.Gml dose group
B =1.2ml dose group




Similar to 4.3.1.1.3. above, each behavioural observation was assigned a score of
1 to 5; with score 1 indicating no reaction and a score of 5 indicating an abnormal
bizzarre behaviour. The mean scores obtained in this function ranged from 2.2
to 3.0. This is the score that was entered in the analysis. An uncorrected F-test
was used. The difference between the groups and between the first and the last
observations within groups were statistical insignificant (p-value = 0.71). This is
depicted in the next Table HIc.
TABLE HIe. ANOVA RESULTS OF THE CLICK RESPONSE SCORES (HP-2)
SOURCE SS 4t MS V.R. p-Value
Among groups 0.0953 2 0.0477 0.5005 0.071
Within groups 1.7142 18 0.0952
TOTAL 1.8095 20 0.1429
df = degrees of freedom, SS = sum of squares, MS = mean squares and V.R. = variance ratio.
4.3.1.2.4 Histopathology Results
The microscopic examination performed on the tissues and organ samples
submitted from this experiment revealed no abnormal lesions. (see Appendix II)
50
4.3.2. DIABETIC CLINICAL TRIAL
Diabetes was induced by a single dose, intraperitoneal administration, of 65
mg/kg body weight of Streptozotocin solution to normal healthy Wistar Albino
rats. The STZ was dissolved in 10ml of normal saline and adjusted to pH 4 with
citric acid buffer of 0.25mol/1.
4.3.2.1. Herbal Preparation -1
The three groups of rats, labelled group X, Y, and Z were given 2ml
Glibenclamide suspension, 2ml Distilled water and 2ml HP-I respectively and
monitored for 26 days with blood glucose tests done on alternative days.
On the first test date, five readings of glucose levels were done at intervals of two
hours. TABLE IV ( overleaf) depicts the average glucose level per group and
the trend observed on the first day is illustrated in Figure 3.
No difference in blood glucose levels were observed at 2, 4, 6, 8 and 10 hours
after the administration of the treatment dose in all groups. A slight increase was
observed with the second reading in all cases, and this tapered slightly towards the
end of the day.
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TABLE IV
ACUTE EFFECT OF HP-I, GLIBENCLAMIDE AND CONTROL ON DIABETIC
RATS
(MEAN GLUCOSE LEVELS IN mmolllL +1- S.E.M.*)
Average Pre-
Treatment Levels
Treatment 1st Reading 2nd Reading 3rd Reading 4th Reading 5th Reading
Ohrs 2hrs 4hrs 6hrs 8hrs
Glibenclamide (X) 14.3 +1- 2.4 25.2 +1- 2.4 22.9 +1- 2.4 20.5 +1- 2.4 21.6 +1- 2.41
I
Control (Y) 11.2 +1- 2.4 20.3 +1- 2.4 19.6 +1- 2.4 14.5 +1- 2.4 17.1 +1- 2.41
I
HP-l (Z) 1.65 +1- 2.4 20.8 +1- 2.4 20.7 +1- 2.4 16.8 +1- 2.4 22.8 +1- 2.41
*S.E.M. is the Standard Error of the Mean
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FIGURE 3
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Using Scheffe's F test in the analysis of variance, the 3 groups of data were not
significantly different from one another at p value of p=0.28 with respect to
average decrease (or lack of it) in level of blood glucose in the test samples.
The experiment was then continued for an additional seventeen days with blood
glucose levels done every second day. Table V relates the blood glucose levels
over this period and Figure 4 demonstrates the trend observed. The blood
glucose levels that demonstrated normoglycaemia of the rats, were excluded to
avoid introduction of a confounding factor in the analysis. The test groups failed
to exhibit hypoglycaemic activity for both HP-I and Control except for the
Glibenclamide group which demonstrated an average of 54% decrease in blood
glucose levels. The HP-l demonstrated a 11% decrease and the Control 0%
decrease in glucose levels.
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TABLE V
CHRONIC EFFECT OF HP-I, GLIBENCLAMIDE AND CONTROL ON DIABETIC
RATS





Groups Day 1 Day 3 Day 5 Day 8 Day 10 Day 12 Day 15 Day 17
Glibenclamide
(X) 16.5 + /-1.9 17.7+/-1.9 15.3 + /-1.9 15.8 + /-1.9 10.6 + /-1.9 12.7 + /-1.9 9.44 + /-1.9 7.49+/-1.9
Control (Y) 5.65 + /-2.7 13.18 + /-2. 8.25+/-2.7 9.55 + /-2.8 10.45 + /-2. 19.03 + /-2. 16.05 + /-2. 15.8 + /-2.8
HP-l (Z) 12.23 + /-3. 8.0 + /-3.18 9.17 + /-3.1 9.47 + /-3.1 7.07+/-3.1 14.7+/-3.1 11.8+/-3.1 9.7+/-3.18
·S.E.M. is the Standard Error of the Mean





























- - - 'Control (Y)
••• - - - HP-1 (Z)
The variance between the two groups (HP-l and the Control) was not
significantly different from each other (p= 0.57). This is illustrated in the
following table (Table VI).
TABLE VI. ANOVA RESULT AT THE END OF HP-l TREATMENT
SOURCE di SS MS F ratio p-Value
Among groups 2 68.014 34.007 0.566 0.575
Within groups 22 1321.720 60.078
TOTAL 24 1389.734 94.085
*df = degrees of freedom, SS = sum of squares, MS = mean squares
4.3.2.1. I.Histopathological Results
The results are presented in Appendix III whereby xxI to xx9 represents
specimens (pancreas, liver and kidney) from the group treated with
Glibenclamide; yyl to yy9 represents the Control group and zzl to zz9 the HP-l
group.
The histological reports indicated very mild to moderate pancreatic and
hepatocellular atrophy, steatitis in the mesenteric fat and multifocal cortical
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tubular dilatation. Most changes were found in the kidney and the liver
specimen. These changes are reported to be mild to moderate and to a degree,
similar in all three groups. Similarly, STZ has been found to be cytotoxic and
the lesions reported are consistent with the pre-neoplastic lesions caused by
cytotoxic and degenerative action of streptozotocin [Prof Kriek, pers comm].
This is consistent with other studies whereby the isolated zona glomerulosa cells
of the STZ-induced diabetic rats, showed a marked atrophy [Andreis et aI, 1990].
The hypothesis is advanced that the chronic lack of insulin may also directly
impair the growth and steroidogenic capacity of the organs in the rat.
4.3.2.2. Herbal Preparation -2
Similarly, the tests on the first day were performed five times (five blood glucose
readings) at two-hour intervals. The results are illustrated in Table VII and
Figure 5 respectively.
A noticeable elevation in blood glucose levels was observed on the first day and
this was not significantly different among the groups (p= 0.23). The results of
the three weeks of experiments, demonstrate a gradual decrease in blood glucose
levels with each treated group average differing from each other by 10% and that
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of the control group remaining almost unchanged. The difference in that group
(control) of glucose levels from day one to the last day of the experiment was 10%
whereas that of HP-2 and Glibenclamide was 59% and 49% respectively. These
results are illustrated in Table VIII and Figure 6.
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TABLE VII
ACUTE EFFECT OF HP-2, GLIBENCLAMIDE AND CONTROL ON DIABETIC RATS
(MEAN GLUCOSE LEVELS mmol/L + /- S.E.M*)
Average Pre-
Treatment Levels
Treatment 1st Reading 2nd Reading 3rd Reading 4th Reading 5th Reading
Ohr 2hrs 4hrs 6hrs 8hrs
HP-2 (A) 12.6 + /- 2.3 16.3 +/- 2.3 15.5 + /- 2.3 19.1 + /- 2.31 19.1 + /- 2.31
Glibenclamide (B) 16.9 + /- 2.3 17.4 +/- 2.3 11.7 +/-2.3 22.8 + /- 2.57 23.5 + /- 2.46
Control (C) 18.4 + /- 2.3 11.1 + /- 2.3 17.95 +/- 2.5 18.9 +/- 2.3 19.7 +/-2.3
*S.E.M. = Standard Error of the Mean
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FIGURE 5
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TABLE VIII
CHRONIC EFFECT OF HP-2, GLIBENCLAMIDE AND CONTROL ON DIABETIC
RATS




Day 1 Day4 Day 6 Day 8 Day 10 Day 13 Day 15 Day 17
HP-2 (A) 15.5 + /-1.5 11.7 +/-1.52 14.33+/-1.52 10.45 +/-1.52 8.83+/-1.52 7.98+/-1.52 8.63+/-1.52 5.9+/-1.52
Gliben-
clamide (B) 20.11+/-2.3 18.1 + /-2.32 16.47 + /-2.32 13.7 + /-2.32 13.21 +/-2.32 12.77 +/-2.3 11.41 + /-2.32 10.49 +/-2.3
Control (C) 15.9 + /-2.01 13.7+/-2.01 12.0 + /-2.01 9.1 +/-2.01 8.8 +/-2.01 4.4+/-2.01 14.6 + /-2.01 10.7+/-2.01
·S.E.M. is the Standard Error of the Mean
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The HP-2 group demonstrated a 59% decrease with Glibenclamide demonstrating
a 49% decrease in blood glucose levels. The control group demonstrated a 1%
decrease in glucose levels. At the end of this experiment the blood glucose
levels under various treatments were significantly different at the 99% confidence
level. This is depicted in the following table.
TABLE IX. ANOVA RESULTS AT THE END OF HP-2 EXPERIMENT.
SOURCE di SS MS F-ratio p-Value
Between groups 2 153.198 76.599 7.227 0.006
Within groups 16 169.589 10.599
TOTAL 18 322.787 87.198
*df =degrees of freedom
4.3.2.2.1. Histopathological Results
These results are also presented in detail in Appendix III whereby Al to A9
represents the specimen (pancreas, liver and kidney) from the HP-2 group, B3 to
B9 the Glibenclamide group and C2 to C9 the Control group respectively. There
was mild sporadic hepatocellular atrophy reported (see Appendix Ill) in some
cells, which were consistent with the endocrinological disturbances caused by
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STZ. In addition to STZ disturbances, the specimen from the two groups treated
with HP-2 and Glibenclamide exhibited steatitis in mesenteric fat tissue and some
hepatocellular fatty changes. Bearing in mind that both Glibenclamide and HP-2
demonstrated a similar hypoglycaemic effect, it is not surprising that lesions seen
on the histopathological examination from the two groups, also exhibit similar
trends in atrophy, hyperplasia and changes in the fatty tissue compared with the
control group. Glibenclamide is reported to have mild lipolytic properties on
adipocytes [Koda-Kimble & Rotblatt, 1995].
Similar lesions on the tissues taken from the liver and kidneys were reported.
These were reported to be of significance and suggested that these may progress
to neoplasia in experiments of longer duration. This is consistent with other
findings and the oncogenic properties of STZ.
4.3.3. ORAL GLUCOSE TOLERANCE TEST RESULTS
It was the intention of this study to do an OGTT at the end of the 26 days, in order
to determine whether there was an improvement in glucose utilization after the
treatment with HPs. According to the OGrr methodology, the glucose bolus is
administered four hours after the various treatments (HP or Glibenclamide) have
been given. In this case, as it was customary, the various treatments were given
first thing in the morning, mixed with a portion of daily ration of food, four hours
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before the administration of glucose. This form of administration of the
treatment doses inadvertently broke the fast, and invalidated the results.
4.3.4. WEIGHT STUDIES RESULTS
A noticeable weight loss was observed in the group treated with HP-1 and this
was comparable to the weight loss in the Glibenclamide group whereas the
control group treated with Distilled water demonstrated a weight gain consistent
with the normal growth process (see Table X and Figure 7).
HP-2 group demonstrated a slight gain in weight compared with both
Glibenclamide and the control groups. Goodman & Gillman (1995) reported
that marijuana smokers frequently reported increased hunger and this could have
lead to overeating and resultant gain in weight over the three weeks of the




AVERAGE WEIGHT IN GRAMS
Treatment Groups Day 1 Day 10 Day 17
Glibenclamide (X) 206 184 176
Control (Y) 199 194 206
HP-l (Z) 193 185 175
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FIGURE 7
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AVERAGE WEIGHT IN GRAMS
Treatment Groups Day 1 Day 10 Day 17
HP-2 (A) 225.7 218.9 230.4
Glibenclamide (B) 173.3 154.9 166.6
Control (C) 219.7 202.7 214
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FIGURE 8
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4.4. GENERAL DISCUSSION OF THE HERBAL PREPARATIONS
The results of this study suggest that acute treatment (first day) with both HPs
failed to exert any hypoglycaemic effect. The HP-l as tested here also failed to
demonstrate any significant hypoglycaemic activity over a period of three weeks.
There could be several explanations for this; the dose used might have been
insufficient (although it was calculated based on body weight and the dose given
to humans) or the added excipients might have had an attenuating effect on the
hypoglycaemic activity of the main ingredients or the HP might have been devoid
of hypoglycaemic activity. What pharmacological effects the individual plants
in the mixture would exert, if and when used alone, was beyond the premise of
this study.
Although no hypoglycaemic effect was demonstrated with HP-I, the individual
constituents have been associated with therapeutic activity in previous research.
The traditional healers believe that if Catharanthus roseus is in combination,
with other medicinal plants, the hypoglycaemic effect is enhanced whereas the
toxic effect is toned down or minimised. Ilabatheka (Hypoxis oligotricha) for an
example, has been found to have anti-emetic properties and used to quell nausea
and vomiting immediately if taken as tea [Pujol, 1990]. Most Zulus and Xhosas
use it to calm the heart and anxiety [Hutchings, 1991]. In what context it was
used here, could not be determined; but aloes are known to be bitter and could
induce vomiting and purgation.
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Several studies on the activities of medicinal plants have documented the
hypoglycaemic effect of some Aloe species [Mossa, 1985; Ghannan et aI, 1986].
The dried sap of the Aloe plant is one of several traditional remedies used in the
treatment of diabetes in the Arabian peninsula since time immemorial [Ajabnoor,
1990]. Ghannan and his co-workers (1986), speculated that the mechanism of
action of aloes is mediated through stimulation of residual insulin secretion from
the l3-cells of Langerhans. Aloe has been found to contain anthraquinone
glycosides, barbaloins and beta-barbaloins, resins and saponins. None of these
individual constituents have shown any antidiabetic effect in the past studies.
The effect that the aloe species (as used in HP-I) would have had, if used alone or
in higher doses, was beyond the scope of this research project. Similarly, the
leaf infusions and decoctions of Catharanthus roseus (periwinkle) have been
reported in a study conducted by Neame and Pillay (1964) to have mild
hypoglycaemic effect in healthy rats. Several alkaloids have been isolated; viz:
leurosine, vindoline and catharanthine. However, the neurologic and cytotoxic
effect of these alkaloids did not encourage further investigation [Bailey et aI,
1985; Day and Bailey, 1988].
Treatment of streptozotocin-diabetic rats with HP-2 for twenty six days resulted in
a noticeable hypoglycaemic effect, and weight gain, and in some cases these
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results were comparable to Glibenc1amide treated group. Again, the antidiabetic
properties of HP-2 could be dose-dependent.
Similarly, previous studies have documented the hypoglycaemic effect of
Momordica foetida {found mostly in Africa} and M. charantia {found mostly in
Asia, Australasia and Central America} used alone or extractions thereof. These
studies suggest that Momordica species have a significant hypoglycaemic activity
and has been widely used to treat diabetes world wide. The glycoside charantin
{which is a mixture of (3-sitosterol-D-glucoside and stigmadine glucoside), found
in these species, was found to inhibit hepatic gluconeogenesis while improving
glycogenesis in healthy and alloxan-induced diabetic rabbits, but found to be
ineffective in pancreatectomized animals [Vad, 1960; Meir et aI, 1985; Keder et
aI, 1982; Leatherdale et aI, 1981; Day and Bailey, 1988; Bailey et aI, 1985].
Other studies cite a polypeptide designated as P-insulin to be responsible for the
antidiabetic action [Iwu, 1993; Bailey & Flatt, 1986]. This insulin-like peptide
has been found to inhibit hepatic gluconeogenesis as well as decreasing intestinal
glucose uptake in the laboratory experiments [Day & Bailey, 1988]. If injected
subcutaneously into Type I diabetic patients, it has been found to lower blood
glucose levels [Murray & Pizzomo, 1990].
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The young shoots of Musa paradisiaea and sapientum have been used for blisters
and wounds in New Guinea from time immemorial. In India it is popularly used
for snakebite wounds [Wheelwright, 1974]. The reason for inclusion of this
species in the herbal preparation could not be determined in this study.
On the contrary, Cannabis sativa which was used in this herbal preparation (HP-2)
has been found to be devoid of antidiabetic activity. Instead, it has been
associated with hyperglycaemia [Goodman & Gillman, 1995]. An infusion of
leaves and stem is said to be used for cough and is also very effective in averting
an acute asthmatic attack [Gumede, 1990]. However, several studies
demonstrated its anti-emetic properties (as tetrahydro-cannabinol isolated from
Cannabis is used for nausea in cancerous patients) and it could have been used in
that context in the HP-2. The bitter gourd or melon (Momordica) is known for
its strong emetic and spasmodic properties sometimes resulting in death [Vad,
1960; Leatherdale et aI, 1981].
The results of the Acute Oral toxicity tests indicates that no toxic reactions or
untowards effects could be attributed to the herbal preparations investigated in
this study. Mild to moderately mild lesions as reported in the results and also in
Appendix 11 and Ill, were found by histopathologist. No mortality was observed
in these experiments for both HP-1 and HP-2.
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The mortality rate in Diabetic clinical experiment was very low; three rats died
prior to the beginning of HP-I experiment with one rat dying four days after the
treatment was initiated. Five died prior to the beginning of the experiment (HP-2
group) resulting in an overall mortality rate of 15% for the whole study. The
death of these animals could be attributed to advanced stage of diabetes and the
degenerative properties of streptozotocin. In the absence of insulin, metabolic
alterations which affect glucose metabolism and homeostasis in the cells, results
in atrophy. The oncogenic properties of STZ also contributed to the formation of
the lesions reported by histopathologists and these (at an advanced stage) could
have contributed to the death of these animals.
In the case of the rat that died after the experiment (HP-I) had begun, the same
reason as above could be the cause or it could be that HP-l could have possible
toxic effects. The combination of the two could have had a synergistic toxic
effect and resulted in death of this rat.
According to the protocol of the study, the OGTT was to be conducted in order to
test the effectiveness of the various antidiabetic treatments after the Diabetic
Clinical Trial. However, the protocol did not stipulate the method of
administration of the treatment doses for this particular experiment. Following
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the method used for the preceding 26 days for the diabetic experiment, the same
method of administration of the treatment doses was used for the OGTT, thus
creating a serious error that invalidated the results. The study could not be
repeated due to lack of funds.
Herbal remedies have been reported to have untowards effects and precautionary
measures need to be taken in dosing. Several studies have documented the toxic
and adverse effects of traditional medicines [Bye and Dutton, 1991; McVann et
aI, 1992; Dunn et aI, 1991; Victor et aI, 1988; Koff, 1995; Macgregor et aI, 1989;
Maurice and Cream, 1989]. It is on this basis that recommendations are made for
more research into medicinal plants and the compilation of herbal remedies
pharmacopoiea [Murray, 1990; Amold and Gulumian, 1984].
Although animal models are used for the testing of safety and efficacy of medical
substances, it should also be borne in mind that substances tested on animals do
not necessarily produce the same effects on humans. As human responses to
medicines are also known to vary from one individual to another, they may vary
from animal to animal [Grundy, 1990] as well. Also, the absence of an effect in
one type of diabetes does not exclude the possibility of an effect on glycaemia in
other types of diabetes or a beneficial effect other than glycaemic control. Thus,
caution should be exercised when extrapolating these results to human beings.
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4.5 Limitations of the Study
Funding was the most crippling and yet an essential part of the study. It was the
intention of the investigator to conduct a number of tests to monitor the progress
and to determine the effectiveness of the various treatments administered to the
animals; tests such as the insulin content at the end of AOTT. However, due to
limited funds, these tests could not be done.
The study design had a flaw as far as randomisation of rats is concerned. The rats
were randomised prior to diabetes induction which created a confounding factor in
the experiment.
Another lesson learned is that the protocol should be explicit in outlining the
methodology to be followed in the experiment and that technicians assisting in
the study should be closely monitored in order to avoid errors such as the one
committed in the OGTT.
4.6 CONCLUSION
Both the herbal preparations {HP-l and HP-2} were found to be non-toxic to the
animals and therefore it is possible that they could be non-toxic and non-
hazardous to human subjects at the concentrations used. HP-2 was found to
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have a sustainable lowering effect on glucose levels over the period of
experimentation. As a result, a reversal of diabetic state or in the least, control of
blood glucose level is a possibility.
The findings of this study however, encourages further research of more similar
studies. Based on these findings the foundation is laid to initiate more research
into medicinal plants used in treating diabetes countrywide and other indigenous






The proposal for the study was reviewed and approved by the Medical Research
Council (MRC) Protocol/Editorial Committee as well as the ethical clearance
given by the Ethics Committee of the University of Durban-Westville. (see
Annexure I & III respectively)
5.1.1. Study Site:
The research was conducted in a rural area in Northern KwaZulu-Natal where the
majority of the population use herbal remedies (self prescription) or patronise
traditional healers in great numbers. The principal investigator (TZ-P) was
familiar and had good rapport with the traditional healers in the area. The
specific localities targeted were Hlabisa, Jozini, Pongola and Hluhluwe as
reflected in Figure 9. These areas were chosen partly because they have easily
accessible hospitals and clinics (for verification of diagnosis as well as the
presence of diabetic clinics) and also the fact that MRC has substations in those
areas which facilitated the gathering of medicinal plants pertinent to the study as

























The study involved interviewing traditional healers (Appendix IV) and their
patients (Appendix V), taking traditional remedies and/or allopathic medicine for
the treatment of diabetes. The target population was therefore the traditional
healers in the areas mentioned; the people who use traditional medicine for this
ailment; as well as people who had diabetes and did not use traditional medicines
to form a control group.
5.1.3. Ethical Considerations.
Because of the sensitive nature of the information required from both patients and
the traditional practitioners, the research study presented a number of
methodological and practical challenges. It was therefore decided, at an early
stage to use both qualitative and quantitative techniques. Qualitative methods
were considered to be appropriate measuring tool to determine the attitudes and
practices in this case. Where necessary, homogeneous groups were selected for
focus group discussions.
It is a well known fact that traditional practitioners keep most of their knowledge
to themselves and those who patronise them do not volunteer information easily;
all because of the stigma and negativism that has been associated with traditional
healing. Hence, a consent form ( Appendix VII) was designed as an agreement
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between the researcher and the respondents that their confidentiality would be
maintained, as well as the intellectual property rights would be protected. The




An observational study - unobtrusive observations with a twelve month's follow-
up (case series) was used. Patients (age range of 20-65 yrs) were stratified into
three groups; those who used traditional medicine only, those who used the herbal
remedies concurrently with allopathic medicine, and those who used allopathic
medicine only. These groups were monitored for a period of 12 months from the
date of enrolment to the study. Interviews with clinical examinations (blood
glucose tests and BP measures) upon enrolment and during the course of the study
were done.
In order to identify users of traditional medicines, a list of healers in the area was
obtained from the National Inyangas Association and the Health Inspectorate in
the four geographic areas. The healers that specialised in treating diabetes, and
gave their consent to participate in the study, were further interviewed. A list of
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the diabetic patients they had treated or were still under their treatment was
requested.
Those patients who agreed to participate in the study and whose diagnoses of
diabetes was confirmed clinically (see Appendix VI) were enrolled.
In order to identify users of allopathic medicine, patients were randomly selected
and interviewed as they attended the diabetic clinics in the study area. If they
gave their consent, they were enrolled and monitored like the other groups.
The inclusion criteria for the three groups were basically, the patient's consent
(Appendix VII), a clinically confirmed diagnosis - Appendix VI - at the clinic,
hospital or doctor's office prior to this interview as well as spot checks of glucose
levels at the site. Those with gestational diabetes were excluded. Initially, it
was envisaged to enrol 120 patients in each group, but due to the logistics and
other problems encountered in searching for patients, this number was reduced,
(see the results) and design adjustments made with the help of the statistician.
The following table (Table XII) show the number of hospitals and clinics
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5.1.4.2. Traditional Healers:
Forty two traditional healers were interviewed. Thirteen were excluded because
they did not or had not treated diabetic patients. Therefore, twenty nine out of
this forty two were enrolled and further interviewed concerning their treatment
for Diabetes mellitus and traditional practice in general.
5.1.4.3. Data Collection Procedure;
It was crucial to the study that the ethnographers were well trained, fluent in the
language, and familiar with traditions and culture of the people in order to build
rapport with the interviewees. These ethnographers had to undergo a day of
training in Zulu customs and traditions as well as sensitised to the rural way of life
by role playing. At the end of the day, they were tested on the knowledge of this
and the manner of approach applicable to different possible scenarios. For
instance, they were instructed not to come with clipboards and a high-handed
attitude but to humble themselves to the extent of joining the activities of the
villagers if possible, and re-schedule their visit for another time. They were also
given an instruction manual of how to fill in the questionnaires, conducting
interviews in Zulu and interpretation to English.
Semi-structured questionnaires (see Appendices IV and V) and one-on-one
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interviews were used as study instruments to compile a detailed medical history
from the time of diabetic diagnosis. Examples of items abstracted from both
hospital/clinic records and interview sessions included date of birth, date of
diabetes diagnosis, sex, age, diabetic treatment, family history and reasons for
clinic encounters or hospital visits and problems encountered that hindered clinic
attendance. The questionnaires used were piloted, pre-tested and adjustments
made before the actual data collection.
5.1.4.4. Interpretation of data
All information was edited for accuracy and consistency before computer entry.
Reliability of the data entered was assessed by re-entering data from a random
five percent sample of respondents, and was found to be highly satisfactory
within error rate of 1.6% (95% confidence interval, 0.8%- 2.7%).
5.2. Follow-up and Outcome Measures
5.2.1. The Dependent Variable:
The progress of the respondents was evaluated after three, six, nine and twelve
months. Both subjective and objective outcome measures was examined. At
each follow up interview, respondents were asked about their perceived health,
generally; any changes and consultations or hospitalisations, symptoms of
complications and the respondents' assessment of the treatment received.
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During analysis where possible, the responses were dichotomised into "positive
results" and "negative results" (1= +ve, 0= -ve) in creating variables. For the rest
of the information, content analysis was performed.
5.2.2. The Independent Variables
A health care services use model was developed to examine the relationship
between the dependent and independent variables [model adapted from the one
used by Andersen et aI, 1974]. Independent variables were grouped into two
domains; the demographic and/or predisposing characteristic; and access to
health care and other issues that may enable or hinder conventional or biomedical
services thus influencing the choice between traditional or conventional medicine.
The demographic characteristics were represented by dichotomous variables for
gender, age, education and employment status.
Characteristics that may hinder access to health care were represented by variables
that included distance, amount of time spent travelling to and from health




Descriptive analyses were used for the main results, the Mantel-Haenszel X2 test,
McNemar test to analyse the outcome measures and multivariate analysis for
association where applicable. The missing data as a result of those lost to follow-
up or incomplete intermittent checks, was analysed by a regression method
whereby an analytic expression matrix of estimated effect was obtained. The
results are given as means with 95% confidence interval and significance was
accepted at the 5% level.
Multivariate models were constructed using forw'ard linear regression, introducing
predisposing, need and enabling variables successively as predictors for
traditional medicine use. To determine the impact of excluding partial
respondents from the models, all but the final stage of each series was run with
their data included; parameter estimates remained virtually unchanged. The
exclusion of partial respondents from analysis appeared to have little impact on
the findings
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5.3. RESULTS AND DISCUSSION
5.3.1 Traditional Practitioners and their Healing Systems
The twenty nine traditional healers interviewed treated various ailments
including diabetes though fourteen (48%) of the healers interviewed were
specialists and tutors or had had initiates and apprentices. The average years in
practice was 14.7 (ranging from 3-41yrs).
They used various medicinal plants (from roots, bark, leaves, flowers and fruits)
including intshungu (Mormodica spp), umgwenya (Harpephyllum spp),
nhliziyonkulu (Dombeya spp), banana (thyrse from Musa spp), inhlaba (Aloe
spp), insangu (Cannabis spp), and tobacco leaves. These were concocted in
different formulations with different excipients added (depending on individual
traditional healer) which included, blue stone, yellow or sour stone (alum),
vinegar etc etc. The medicinal plants were collected at any time as needed but
most of the healers preferred summer season. The reason for that could not be
determined. All the healers interviewed willingly shared their recipes for the
formulation except for nine (31% ) who demanded money for them to disclose
what their ancestors has "alloted" to them - their life line.
The ingredients were chopped or sometimes dried before use, and boiled for a few
minutes or just brought to boiling point then cooled. The dose varied with
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individuals, from a spoonful to a cupful, three times a day and the duration would
be two weeks to three months, before the results are noticeable. According to the
traditional healers most patients needed two or three repeat visits and never came
back. Though this was a subjective assessment, they strongly believed that their
patients were cured, especially because they referred other people with similar
ailments to them (traditional healers).
Upon being asked whether collaboration between ethnomedicine and biomedicine
was a feasible venture most of them (22 {76 %}) agreed that both sectors had
something to offer the patient. There are certain diseases and ailments that they
believe can only be appropriately treated by traditional medicine, and similarly,
certain ailments can only be treated by western doctors. Given that, they
expressed a need for additional training of traditional practitioners in some aspects
of health such as hygiene. They also believed that they need certification or
licences to be recognised as equals to western doctors. Five (17 %) felt that there
is a need for government support in building traditional medicine hospitals and
clinics where they can treat patients and then their performance judged on equal
basis to that of western practitioners. In order to be able to offer a "holistic"
treatment to patients, they believe collaborative efforts between providers of both
sectors should be pursued. They take pride in the fact that people came from
hospitals to seek their treatment and that there were referrals from various parts of
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the country (mostly by other patients previously treated). There were some cases
where referrals were made by doctors and nurses.
They felt there would be no competition between the two sectors, because western
medicine has its place and they respect that. They cited oxygen and other hi-tech
equipment that is used in hospitals but equally demand respect for their own form
of treatment and healing systems.
Seven (24%) adamantly opposed any form of collaboration, the reason being
that the doctors looked down upon traditional healers. Unless that attitude is
addressed and enough mutual trust developed between the two sectors and
doctors started referring patients to them, they did not see any collaboration at all
with the conventional medical practitioners. Some of them believe that all the
western practitioners wanted to do was to steal their secretive knowledge of
medicinal plants without them (traditional healers), getting acknowledgement or
remuneration as originators of the treatment. Three out of this seven, felt
strongly that traditional medicine is potent and should not be used with
conventional medicine.
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5.3.2. Observational Study of the Diabetic Cohort
A total of 222 patients (respondents with confirmed clinical diagnosis of Diabetes
mellitus) were interviewed, gave their consent and were enrolled for the study.
Nine were insulin dependent and four did not have a confirmed diagnosis and
were all excluded. Thirteen (6.9%) were lost to follow-up. One hundred and
ninety five - 195 i.e. { 56 (28.7%) using traditional medicine only, 97 (49.7%)
taking conventional medicine and 42 (21.5%) using both} were monitored for
twelve months with intermittent checks every three months. Figure 10 - THE
PIE CHART) overleaf is an illustration of responders. The mean age was 51.1
+/- 12.9 years (range 20- 62) years. The median duration of the disease was 5.9
(0 - 51) years.
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FIGURE 10




Group A =Traditional Medicine Users
Group B =Allopathic Medicine Users







DISTRIBUTION OF SAMPLE DEMOGRAPHIC CHARACTERISTICS
BY GROUPS
--------------------------------------------------------------------------------
Group A GroupB GroupC
Characteristics n =56 (28.7%) n =97 (49.7%) n =42(21.5%)
Age 20-29 0 4 3
30-39 5 12 2
30-49 17 19 6
50-59 26 43 21










Pensioners 17 27 12
Homemakers 26 43 16
Employed 5 11 7
Not-employed 6 8 5
Other 2 8 2
========================================================
Total
Male / Female ratio
195 =100%
2:5
* A== Traditional Medicine Users, B== Allopathic Medicine Users, C== Both Medicine users.
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5.3.2.1 The Characteristics of the users of Herbal Remedies (Group A)
The average age was 49.4 yrs (range 27-62) with seven male and forty nine
female. They were mostly pensioners and homemakers which makes them an
indigent group as far as income is concerned. Only 5 (12%) were employed and
money was a problem for most (money for clinic fees when they had to pay and
transport). Few lived at a distance that was over 40 km from the nearest clinic or
hospital. Most of them lived within 20km and yet, transportation cost was
commonly cited as the reason for poor clinic attendance. The commonly
prescribed antidiabetic drug on their record cards (when they attended a diabetic
clinic) was noted to be glibenclamide though sometimes metformin was added.
The majority of traditional medicine users 52 (93%) believed that the herbal
preparations they used was effective and none of them had been admitted for
ailments that suggested herbal poisoning and two in this group actually thought
that the tablets they get at the clinic makes them feel worse. Neame and partner
in 1964, reported fatal hypoglycaemia after consumption of unspecified herbal
medicine in a study conducted in South Africa and this was associated with
hepatic and renal necrosis. Du et aI, 1995, reported several episodes of adverse
events associated with the use of Chinese herbal medicines. No reports of
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complications or mortalities were associated with the herbal remedies used in this
study. Only 2% of this group, complained of diarrhoea and had to stop using the
herbal preparation though they found it useful in controlling blood sugar.
Out of the whole group (n=56), 3 (5%) were hesitant as far as the effectiveness of
the herbal remedies were concerned, and only one was definitely convinced that
traditional medicine does not work.
5.3.2.2. Characteristics of the users of Allopathic Medicine (Group B)
Unlike the above group that comprised seven times more females than males, the
gender distribution in this group was in the ratio of 1:2. Their ages ranged
between 28 and 64 yrs, with an average of 51years. Similar employment status
to the first group was reported by these respondents with largely pensioners and
homemakers making up the majority. Fifty five (57%) lived within 5 km of a
health centre and only 11 (11%) lived at a distance over forty kilometres. The
clinic fees and waiting times were the most reasons for not attending diabetic
clinics regularly. They only went to the clinic when there was no medication left,
when they were sick or need to check on their sugar levels or blood pressure.
More often, where and when possible, they simply sent their relatives to collect
medication for them.
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5.3.2.3.The Characteristics of the users of Herbal Remedies and Allopathic Medicine
(Group C)
The average age of this group was 49.6 (range 36-65) years with a similar ratio
(l: 2) male to female to the allopathic medicine users group. Most of them were
again homemakers and pensioners comprising 79% of the group. Only 17%
was employed (including self-employed). They mostly lived within 20km of
hospital or health centre and this (distance and transport cost) was cited as the
most common hindrance to clinic attendance. Few (9.5%) lived at a distance
above 40km.
Distance meant different things to different people; some to private doctors or
traditional healers (by-passing nearby clinics and hospitals).
The most intriguing aspect of this group was that most of them were using
traditional medicine that was self-prescribed. Either they got it (herbal
preparation) from the "bus stop", or pick up intshungu from the veld themselves,
used garlic or followed "chemist's advise" on alternative medicine to
conventional sulfonylureas prescribed. The 'alternative medicine' (self-
medication) they bought mostly from pharmacy shops was" isibiba samaNdiya"
and garlic tablets. Upon investigation this turned out to be dried aloe sap that is
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sold in brown crystal form. Few (33%) got their herbal remedies from traditional
healers.
There was this perception that if one had to take medication for a chronic disease,
it was necessary to periodically substitute this with herbal remedy in order to give
the body a rest from medication and its blood impurities.
Glibenclamide (Daonil ® or Glycomin ®), sometimes with metformin (Dextin ®
or Glucophage ®) added, were the most commonly prescribed conventional
medicine used. Tolbutamide (Rastinon ®) and Gliclazide (Diamicron ®) were
rarely used.
Similar to the above two groups (Group A & B) financial problems and distance
were the major causes for defaults in clinic attendance. The reasons that made
them go to health facilities were illness, collecting medication and checking
glucose levels or blood pressure. Only one member of this group belonged to a
medical aid scheme.
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The majority. twenty nine respondents (69%) from this group were convinced that
their glucose levels were controlled because of the use of herbal medicines. Three
(7%) was borderline and one (2.4%) emphatically said it had no effect.
The following table ( Table XIV) depicts some of the common reasons that were




FACTORS INFLUENCING DIABETIC CLINIC ATTENDANCE
FEATURES HINDERING REGULAR CLINIC ATTENDANCE (n=195)
• Distance and transportation (29.7%)
• Costs and clinic fees (32.3%)
• Waiting times at the clinic (11.3%)
• Lack of appropriate care, critical tests and procedures, drugs (8.2%)
• Getting time off work (1.5%)
REASONS FOR ATTENDING HEALTH FACILITIES (n=195)
• Sickness (mostly not diabetic related) (33.8%)
• Replenishing medication (51.8%)
• Need to check blood glucose levels and blood pressure (35%)
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5.3.2.4. Concomitants of Diabetic Clinic Attendance
A very small percentage, 2% of the respondents (n=195) had medical insurance.
'In the absence of medical aid, they were relying on the state health for their health
care needs. According to the Andersen and Aday model (1974), health services
utilisation is influenced by predisposing, need and enabling factors.
5.3.2.4.1. Need Characteristics
Need characteristics relate to perceived or self-rated health status and they could
be subjective or objective if a medical status scale is constructed and used as a
measure. How one perceives his or her physical health and functional ability
determines when they should pay a visit to a health centre or a doctor.
Once the need has been established, other factors; enabling and predisposing
factors are considered. In this study, the need comprised of medication, to




These are measures of use of health services and their affordability - those factors
that hinder or facilitate use of a service once a need has been recognised. The
hindrance mostly frequently mentioned was the respondents financial status.
Most of them were pensioners or homemakers (which means they depended on
husbands or relatives who were migrant workers somewhere far away, for
income). As a result, the distance to the nearest clinic, though most of them lived
within 20km, and the transport cost was a big issue. They also, at some stage in
the study (though this was later changed to free, early in 1995) had to pay R3 - R4
clinic fees. That, coupled with transport costs and waiting times at the health
centres, contributed towards the poor clinic attendance.
Distance and transport costs meant different things to different people. Those
who favoured the use of traditional medicine for their illness, complained that the
healer who could or had helped them in the past was located far away and they
could not go there as regularly as they wanted. Some did not seem to mind
paying the traditional healer's fee (R60-R120) compared to the low clinic fees.
On the other hand, they may have been desperate to be cured, if they thought that
the biomedicine was not of any help.
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5.3.2.4.3. Predisposing Characteristics
These are exogenous characteristics of individuals that may affect need or
recognition of need for health care services including physical functionality of the
individual. The perceived state of physical health or impaired functional status
coupled with depression and anxiety, influenced the respondents willingness to
attend regular clinics. The level of education of respondents and their
understanding of the disease state played a major role in the regularity or
irregularity of their attendance. The study site being in a rural area, most of the
respondents had very little understanding of the disease and what they should do
to control it or prevent complications.
Another contributory factor was the shortage of drugs or lack of testing
equipment related to their disease; blood glucose tests or even urine strips were
often not available.
These factors explained 21% of variation in diabetic clinics attendance.
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5.3.2.5. Comparative Overview of the need, enabling and predisposing factors
The predisposing characteristics contributed minimally to the amount of variance
- only 0.8% in the use of traditional medicine. Need characteristics explained
6% of variance; self-assessed health was statistically significant with self-rated
health being more important than other characteristics. Those who were
objectively or subjectively in poorer health or had poor control of their blood
glucose, were more likely to be taking both traditional remedies and allopathic
medication. Hence, the reports of monilial infection and blurred vision were
more commonly reported by this group (Group C).
It therefore comes as no surprise that poor control of glucose levels (symptomatic)
and the presence of a chronic condition, seems to be the major determinant of
traditional medicine use. The factors influencing the choice of traditional
medicine use being better explained by multiple factors rather than by a single
characteristic.
5.3.3. Disease Outcome Measures.
Adherence to treatment was very erratic across the board. The respondents
adherence to a treatment schedule, whether conventional or traditional, indicated
desperation and lack of knowledge of the disease process and management. Very
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few 23 (12%) took their medication regularly, followed the recommended diet
strictly or exercised regularly as recommended. Only four (2.1%) did self-
monitoring procedures such as checking their own urine or blood glucose levels,
mostly because they could not afford to buy the necessary equipment such as
glucometers and dipsticks. More often than not, they would try several treatment
regimes, or go without treatment for weeks (as long as there were no severe
symptoms of hyperglycaemia) when they could not go to clinics or healers.
Transport, money or medicine being out of stock at the clinics were cited as the
general reasons.
Logistic regression analysis was performed to assess the independent nature of the
risk factors for Diabetes mellitus (elevated Blood Pressure {BP}, gender and
age). A significant correlation was observed between the levels of diabetes and
hypertension demonstrating a higWy significant trend with age (p < 0.5).
Variables known to be associated with hypertension risk in the general population
[Sprafka et aI, 1988; Sharma et aI, 1989; Chahal et al, 1985] were also associated
with hypertension among diabetic individuals, i.e. older age (Odds ratio (OR) =
4.1), being female (OR =3.9) and hypertensive (OR =3.8) were significant
independent risk factors for diabetes.
The summary of this analysis is presented in Table XV overleaf.
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TABLE XV
MULTIVARIATE ANALYSIS OF RISK FACTORS ASSOCIATED WITH
DIABETES MELLITUS IN THE SAMPLE
Odds Ratio (OR) 95% Confidence
Interval
Age 20-29 0.9 0.4-1.7
30-39 1.4 0.9-2.1
40-49 2.8 * 1.8-4.4













*Statistically significant, p< 0.05.
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Diabetic foot ulceration, was the most common complication of diabetes found to
occur in all three groups. Because of poor care, and lack of advice on nail care
and hygiene by health care workers, this was common in 63% (123 out of 195) of
the respondents. The presence of callus (a known predictor of ulceration) was
reported by 47% of respondents and this was evidently the greatest cause for
concern among the respondents. Three amputations were recorded during the
study period of which two were sample members. This variable was a highly
significant predictor of poor control and poor monitoring of blood sugar levels.
Regular measurement of haemoglobin A1c values enables the prescriber to adjust
the treatment regime according to levels thus improving the metabolic and blood
glucose control with a subsequent improved diabetic control as a whole in a
clinical setting [Nathan et aI, 1984; Schwartz & Clancy, 1984; Gabbay et aI,
1977; Sharma et aI, 1989; Goldstein et aI, 1982; Anon, 1980; Stickland et aI,
1984; Larsen et aI, 1990]. It was the intention of this study project to measure
the HbA1c levels, at least at three-months intervals and compare the trends.
However, due to financial constraints and other related resources, these tests were
not completed.
Consequently, the initial HbA1c levels recorded when the respondents were
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enrolled could not be compared with anything. The initial levels recorded were
markedly elevated in all three groups (12.37 +/-0.46 g/dl) and were found to be
highly significant (p< 0.001). The normal range is 5.5 - 8.5 g/dl. Out of 211
diabetic patients that were admitted at Hlabisa Hospital during the twelve months
of the study period, 29 (14%) had blood glucose levels that were erratic. In the
current study, 3.1% (6 out of 195 respondents) had three or four follow-up
interviews with complete blood glucose levels. Consequently, this parameter
could not provide meaningful comparison of the groups.
Depression in diabetes resulting from, or leading to family dysfunction and
eventual floundering in the diabetic control, was not uncommon. Winocour et aI,
1990; in their study, found abnormal depression ratings more in women than
men, although a notably low feeling of anxiety and insecurity was observed more
frequently in men. It was beyond the premise of this study project to measure
that quantitatively, but a subjective assessment (from patients themselves)
indicated a similar pattern of insecurities and depression. This was due to several
factors; the lack of control of their ailment and the complications thus resulting,
the attention given to them by health workers, the procedures (or lack of them)
performed such as blood glucose tests or BP measurements. It was observed that
in most diabetic clinics, patients were only given their monthly supply (which
sometimes was out of stock - more often than not) and sent home.
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No proper education and counselling was given to them at the diabetic clinics
about foot care, diet, importance of proper sugar control, exercise etc. Several
studies [Wensing et aI, 1994; Cleary et aI, 1988; Bestvater et aI, 1988; &
Cymbalist et al,1988; Skyler, 1978] that dealt with patient satisfaction as an
indicator of quality care, showed that patient involvement in their own care
contributes to the quality of that care. They discovered that this can be improved
when a patient contributes towards his/her own care, by being made to feel they
are part of the team.
Firstly, if patients are well informed by providers about their disease state and
the prognosis, and secondly, being given responsibility to monitor certain aspects
of care, such as diet, self-monitoring (BP or glucose measures) etc, they are made
to feel responsible and learn to manage their disease state much better [Balant,
1981; Skyler, 1978; Koda-Kimble et aI, 1995; Jackson et aI, 1981]. This was
partly one of the reasons why patients resorted to traditional medicine when their
blood sugar levels were uncontrolled and also the reason that led to depression
and anxiety. This was found to be more common in the groups using traditional
medicine either alone or together with the conventional medicine (p = 0.019) than
the group using allopathic medicine only.
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Edeling et al in their study conducted in the Free State in 1990 reported that 12%
of Black diabetic patients were referred for routine eye care. Most of them were
referred with visual acuity of 6/18 or worse. Many were seen very late with an
advanced sight-threatening retinopathy. In this study, very few +/- 5% reported
to have been referred for ophthalmological care though complaints about blurred
vision were common across the board in all three groups - 138 (71%). The exact
extent of this and any other changes of the retina that usually occur with poor
control could not be determined .
Second to complaints of blurred vision, were complaints of monilial infection
(indicated by respondents reporting itching and skin rash in the groin areas) which
were recorded in 76% of cases in their follow-up interviews. This was more
common in the group using both traditional and conventional medicine - Group
C (p-value=0.021).
None the less, 29% of those who said they preferred modem medicine, used a
combination of modem and traditional medicines. Culturally based myths and
beliefs play a large role in the perceptions and attitudes towards diabetes
treatment in black communities.
110
Those who preferred traditional medicine cited the following reasons for
patronising it; cost, closer and accessible, no intimidation, and better attention,
and the fact that traditional medicine can find social causes of the illness (e.g.
witchcraft and supernatural) and other manifestation of a disturbed equilibrium of
life.
Overall, responses of the patients to the survey concerning their attitude towards
health care especially diabetes care, reflected that the respondents' attitudes
were consistent with the findings of other studies [Anderson et aI, 1990]. These
studies, conducted in Michigan, came up with factors representing patient's
attitude towards the need for special training for those who provide diabetic care,
patient autonomy, patient compliance and team involvement of both patients and
providers. In this study, patients felt alone and were not satisfied with the kind
of treatment they received. Consequently, they had to do what they thought was
best for them in order to survive.
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5.4. Limitation of the Study
Some of the important limitations of the study must be recognised. First, non-
randomized clinical trials are susceptible to numerous types of bias, including
selection bias; and this trial was no exception.
5.4.1. Sampling:
Convenience sampling may be an easy way out, especially in studies like this that
are conducted in a rural area with no street addresses, or telephones to conduct
meaningful follow -up interviews and transportation problems abound, but they
might not give reliable information. With better planning and availability of
funds, the trial could improve greatly and we hope to do that at a later stage. For
this particular case it was sufficient to monitor the disease outcome in addition to
HbA1c; the incidence of vision deterioration, kidney complications, gangrene or
other skin disorders associated with Diabetes mellitus.
5.4.2 Confounders:
The second limitation involved the difficulty in analysing the confounding effect
of past drug use (be it traditional or conventional) in evaluating the present
pattern. This could not be ruled out and it might have affected the present results
somewhat.
112
5.4.3. Beliefs and Religion:
A third limitation relates to fear of religious and social disapproval ( especially
from modem medical practitioners and "christians") that is connected to the
stigma attached to the use of traditional medicine, may well have made some
respondents reluctant to admit that they used any traditional remedies and thus
biased the data in favour of modem medicine and self-medication.
5.4.4. Sample Size:
The fourth limitation is related to the size of the sample. As explained earlier,
due to the difficulty encountered in tracing the patients in a rural setting, the
originally calculated sample size was not attained. In addition, not all the
respondents who were enrolled could be followed throughout the period of the
study. Due to attrition, 16% were lost to follow up. Though this was taken into
consideration in the final analysis of covariance, the effect it had on the
diminishing sample size cannot be overlooked. Thus, the number of patients
studied and followed up represents a relatively small "slice" of diabetic patients
in the study areas.
5.4.5. Monitoring Tests:
It was the intention of this study to monitor blood glucose levels of the patients on
regular basis as well as the glycosylated haemoglobin levels in order to establish
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the effectiveness of the medication the subjects were taking (be it herbal remedy,
allopathic medication or both). The blood glucose levels collected could not
yield meaningful results because of the attendance of the respondents at the
diabetic clinics. This was very erratic and riddled with gaps of non-attendance
for any trends and patterns (of the blood glucose levels) to be established. With
regard to HbAlc, the tests were too costly and the limited funding of the project
could not accommodate the cost. In addition, there were serious logistic issues
regarding transportation of these samples to the laboratory from clinics (approx
600km away) in a timely fashion, that could not be overcome.
5.4.6. Quality of data in Medical Records:
Although an attempt was made to use reliable and valid methods to collect data,
the measurement work was restricted to information available from medical
records (which were often incomplete) and inherent limitations of self-reported
information.
5.4.7. Analytical Bias:
Last but not least, even though statistical methods were used in "adjusting" results




The findings of these studies in human subjects, although observational, and
uncontrolled demonstrate patient satisfaction with the results they obtained in
using alternative or traditional medicine. The sustainability of prolonged
glucose-lowering effect of these herbal preparations were not confirmed. No
untoward effects or reaction was attributed to the use of the herbal remedies.
These results have important implications for health policy planning as well as
other care services and there is indeed a need to implement appropriate therapeutic
strategies. This study should serve as a springboard for more studies, with better
control and more generalisability available which is lacking in this study.
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Chapter 6
6.1. FUTURE CONSIDERATIONS AND SUMMING UP
This study was successful in achieving its initial objective; that of preliminary
evaluating the safety and efficacy of the herbal remedies used in Northern
KwaZulu-Natal in the treatment of Diabetes mellitus. HP-2 demonstrated
hypoglycaemic effect that was comparable to that of Glibenclamide. Although
HP-1 failed to exhibit noticeable antidiabetic effect, under different conditions it
could have some therapeutic value. The results of the epidemiological study
were even more intriguing than anticipated in the sense that in addition to positive
results, the study also managed to glean and uncover much more in depth insight
of the reasons, the attitudes and acceptability of traditional medicine, the problems
encountered in attending diabetic clinics by rural communities and the quality of
care given in these areas.
Traditional Medicine has many advantages as well as disadvantages that need to
be carefully considered, for the benefit of health care delivery to all people
[Abdool Karim et aI, 1994; Gumede, 1990]. The advantages of traditional
medicines include the fact that they are accessible, and sometimes more
acceptable to a larger population [Anyinam, 1987; Green & Makhubu, 1984;
Upvall, 1992]. The disadvantages include imprecise and sometimes doubtful
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efficacy, could be unhygienic and may sometimes have a witchcraft aspect to it.
However, if these are addressed, traditional medicine can become an integral part
of health care delivery.
On the other hand, synthetic products used, do not cure diabetes and they do not
necessarily correct the fundamental biochemical lesions or reinstate a normal
pattern of glucose homeostasis in diabetic patient. Scientists therefore have a
great responsibility and challenge to redress the neglect which many of their
colleagues of the past accorded traditional medicine and should continue seeking
a cure for this crippling disease.
Self-monitoring - a key to management and control of sugar levels in Diabetes
mellitus, was not encouraged. The majority of respondents have never checked
their own urine sugar levels, let alone blood glucose tests. They only rely on
clinic nurses, once a month, or even less than that if relatives are sent to collect
medication for them or when the tests materials are temporarily unavailable at the
clinic. Findings of this study showed great need for education for those




6.2.1. The doses for traditional medicines needs to be refined and standardised.
This is only possible with more research of herbal medicines.
6.2.2. Only 5-15% of the world's plants have been scientifically investigated
[Abebe,1990]. The government should channel more funds into traditional
medicines research such as TRAMED, various universities that conduct research
in indigenous medicinal plants, conservation strategies and formal institutes of
traditional practitioners and traditional healing systems. This would serve to
encourage researchers to conduct more controlled studies of microvascular,
macrovascular or neuropathic complications that are usually associated with
traditional therapies.
6.2.3. Collection and dissemination of information pertaining to traditional
medicine. A kind of a database coupled with a clearing house for this
information that could be accessible to both traditional and medical practitioners.
6.2.4. Educational programmes with the aim to educate the community and the
traditional healers as well as to change the attitudes of biomedical sector members
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and allied professions on proper diabetic care education. Failure to counsel
patients appropriately and adequately can mask serious underlying problems
which otherwise could be identified at an early stage before complications set in.
6.2.5. Set up a multidisciplinary research programme including various aspects of
medicinal plant research, validation of popular traditional medicine therapies and
promotion of research activities on the integration of various systems of medicine.
6.2.6. A creation of a national drug formulary or pharmacopoiea of traditional
medicines would very useful.
6.3. FINAL COMMENTS
As a final conclusion, one can say that the importance of Traditional medicine
cannot be underestimated, it will have to play a significant role in South Africa in
delivery of health care. Since the two forms of medical care continue to coexist
and complement each other to a certain extent, they should find ways to
collaborate actively. In the interest of the patient, who is the first priority,
community health programmes must take cognizance of the cultural realities of
the population. These results have important implications for health policy and
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other care services in an attempt to provide and maintain quality and higher levels
of health care for the rural masses.
Validation studies on locally used plant remedies for the treatment of diabetes,
could lead to the adoption of some safe and affordable remedies that are
acceptable to both patients, medical and traditional practitioners. For South
Africa the primary health care potential is enormous, if its medicinal plant
resources are fully exploited. It seems more appropriate to give serious
consideration to indigenous medicinal plants where the majority of the
population's medical health care is largely served by medicinal flora.
This work should be viewed as early, path-finding research in this direction to
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Dear Ms Ziqubu- Page
CHANGE OF TITLE
I have pleasure in informing you that your request for a change
of title has been approved by the University Senex. Your title
now reads as follows:
If AN INVESTIGATION OF THE HERBAL REMEDIES USED BY TRADITIONAL
HEALERS IN IN NORTHERN NATAL A..lIID THEIR EFFECT ON BLOOD GLUCOSE
LEVEL lf •






GRADUATE AND INTERNATIONAL STUDIES UNIT
c.c. Prof M A Seedat
Prof C ;vI Da'~ :~or
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Ptosis (eyelids drooping approximately halfway)
Eyelids completely shut
Cannot observe eyes without disturbing the animal
Observations while Handling - Reswnsels
1. Ease of removing from cage
1 - Very easy (body limp, no resistance, unresponsive)
2 - Easy (little resistance to being picked up, maybe vocalization)
3 - Moderately difficult (rodent rears and shies away)
4 - Difficult (nms around cage, hard to grab)
5 - Very difficult (tail and throat rattles, attempts to bite)
6 - Other (describe)
2. Ease of handling rodent in hand
1 - Very easy (does not resist handling, completely unresponsive)
2 - Easy (does not resist handling but is alert, some movement)
3 - Moderately difficult (rigid, tense)
4 - Difficult (sqUirming, twisting)
5 _. Very difficult (sqUirming, twisting, and attempts to bite)







1 - Eyes wide open
2 - Eyelids slightly droopLTJg
3 - Ptosis (eyelids drooping approximately halfway)











ObServation in the Open field
1. Rears- defined as each time the animal raises up and the front legs come completely off the
horizontal sunace. This includes when the aniJ;n,al uses the side or lip of a cart top as
suppon.
2. Defecation (at end of 3 min)
# - specify number of fecal boluses on paper
D - Diatrhea
3. Urination (at end of 3 min)
# - Specify number of pools of urine on paper
X - Overlapping pools of urine (count number of overlapping pools)
4. Conic Convulsions
1 - None
2 - Chewing (clonus ofjaw)
3 - Quivers of limbs, ears, head, skin
4 - Mild tremors, jerking
5 - Whole body tremors
5. Tonic Convulsions
1 - None
2 - Tonic (constant contraction and extension of limbs)
3 - Opisthotonus (head, body and limbs rigidly arched backwards)
4 - Emprosthotonus (head, b<xly and limbs extended forwards)
5 - Popcorn (animal repeatedly pops in air)
6 - Asphyxial (bout of severe clonic-tonic convulsions resulting in difficult
respiration, posttictal depression or death)
______________ ...,.....-.......~_•.•,....,.~:w'_.._....x"C"'4~" .... _
6. Gait Type
N - NOIIIlal
A - Ataxic. excessive swaying, rocki..,g or lurching
H - ... Hindlimbs splayed or dragging
FO - Feet marlcedly pointing outwards from body
F - Front limbs dragging, unable to supper.: body
HU - Hunched body
T - Walks on tiptoe
F - Body drags or is·flattened against surface
M - Insufficient Spontaneous Movement to assess gait
7. Gait Score - ranking of gait abnoIIIlalities
1- Normal
2 - Slightly abnoIIIlal
3 - Moderately abnormal
4 - Totally abnoIIIlal
5·. Insufficient Spontaneous Movement to score gait
8. Mobility Score
1 - NOI:mal
2 - Slightly impaired
3 - Moderately impaired
4 - Totally impaired (ataxic)
5 - Insufficient Spontaneous Movement to score mobility
9. Level of Arousal
1 • Very low (comatose, stUpOr)
2 - Low (somewhat stuporous but with some head and/or body movement,
exploratory movement virtually absent)
3 • Slightly low (slight stupor, some exploratory movements with periods of
immobility longer than approximately 30 seconds)
4 - Normal (alert, exploratory movements)
5 - Slightly high (excited, tense, sudden~g or freezing)






11. Stereotypy - record any behaviors that are excessive or repetltlve such as circling,
stereotypic groomillg, pacing, repetitive sniffing, or head weaving.
1 - None
2 - Yes (describe)
, 12. Bizarre Behavior
1- None
2 - Yes (describe)
Observation ofReflexes








Normal rat slowly approaches and sniffs or turns away
More energetic response than 3, includes vocalizations




Touch Response (touch rump gently with blunt object).
1 - No reaction
2 - Slight reaction, some evidence that touch was felt
3 - Normal (may slowly turn or walk away)
4 - More energetic than 3, may vocalize
5 - Bizarre reaction (jumps, bites, attacks)
c:..\'c.~
Oick Response (use a metal~ to make one sharp sudden noise).
1 - No reaction
2 - Slight reaction, some evidence that noise was heard
3 - Normal (star-Jes, alerts and freezes)
4 - Increased Reaction
5 - Bizarre reaction Uumps, bites, attacks)
~.......~,~~
Tail Pinch Response (metal i\r;eczers are used to squeeze the tail approximately 2 cm from
tip).
1 - No reaction
2 - Slight reaction, some evidence that pinch was felt
3 - Normal (may turn or walk away)
4 - Increased reaction (more energetic than 3, may vocalize)
5 - Bizarre reaction Uumps. bites, attacks)
5. Pupil Response - The beam of a penlight flashlight is brought in from the side of the




Pupil does not constrict
Pupil highly constricted
\. ~ ,
6. Air Righting Reflex (rodent is held in a supine position. dr-:-pp;:d from 3: I:'~i~t of





Lands with~ ieet on the ground
Tr",.~.~- eel landin'- ••\AJUlI..llllat g
Lands on back
Does not move for 20 seconds
7. La=.e::g Feet Splay - refer to tHe €I:ffi'€Ht f'e"l'i'!ieH ef TOX/C03.
8. Forelimb Grip Strength - refer to me SlmeFH re,j:jiOft ef TOX/004.
9. Hindlimb Grip Strength - referto the 6a~Ht red:!ion of TOX/OO3.
10. Body Temperature - record rectal temperature. Refer to the Cl'n:e:Rt ;egisiQH ef :rOX/006.
11. Other (mcludes tom toenails, broken teeth, and any other findings which may confound
data).
APPENDIX 11
Ref: s1995 - 2024.95






Prtvale Bag X04 OtKleBlepoort 0110 Republic 01 South AIrica
Tel (012) 52&-aOOO Fax (012) 5<16-3102
Faculty of Veterinary Science
Department of Pathology
Fax no. (012) 529 8303
29 August 1995
HISTOPATHOLOGY REPORT: BIOLOGICAL ASSESSMENT - MRS ZIQUBE-PAGE
Your reference: MPK/am; Our reference: S1995/95 - S2024/95; Date submitted: 23 August 1995
Species: Rat; Breed: (Sprague Dawley)
Specimen(s): Pancreas, liver and kidney in formalin for histopathology
RESULTS:
Three groups of rats (X,Y and Z, each containing ten rats) were submitted for histopathology.
Specimens of the liver, kidney, spleen and pancreas were examined for each of the rats. Sections
were processed routinely for histopathology and stained with haematoxylon and eosin, and
.examined with a standard light microscope
No specific lesions were detected in any of the groups. In all the groups a number of animals
manifested scant to moderate accumulations of protein droplets (hyaline droplets) in the epithelial
cells of the proximal convoluted tubules. These changes were not associated with specific lesions
in the glomeruli
COMMENT: No lesions were detected in the three groups. The hyaline droplets reflect some
glomerular damage, which appears to reflect th,e onset of chronic progressive nephropathy that is
known to be a characteristic of Sprague-Dawley rats (Alden & Frith, 1991)
It thus appears that the compounds tested had no morphological effects at the levels administered,
or that the time period of exposure was too short to detect toxic effects
If you need to further discuss the findings, feel free to contact me at any time
Yours sincerely
N P J KRIEK
PROF AND HEAD: DEPARTMENT OF PATHOLOGY
Ref: Alden, C. L. & Frith, C. H., 1991. Urinary system In: Haschek, W. M. & Rousseau, C. G.,
Handbook of Toxicologic Pathology, p. 365
ber 1995'22 Novem
Ref. No. Histo no. Remarks
Al s2889.95 No lesions seen
A2 s2890.95 No lesions seen
A3 s2891.95 Mild to moderate multifocal tubular necrosis and ceil swelling. Numerous hyaline droplets
in the proximal tubular cells. No other lesions seen
A4 s2892.95 No lesions seen
A5 s2893.95 No lesions seen
A6 s2894.95 No lesions seen
A7 s2895.·95 No lesions seen
A8 52919.95 No lesions seen
AS s2896.95 Na lesions seen
Al0 s2897.95 No lesions seen
Bl s2898.95 Few single necrotic hepatocytes; No other lesions seen
B2 s2899.95 Few foci of very mild hyaline droplet accumulation in the proximal convoluted tubules; no
other lesions seen
B3 s2900.95 Mild scattered fatty changes in the liver (without specific distribution); No other lesions
seen
B4 s2901.95 No lesions seen
B5 s2902.95 Very mild multifocal hyaline droplet accumulation in proximal convoluted tubular cells.
Odd single necrotic cells were also present; No other lesions seen
B6 s2903.95 No lesions seen
B7 s2904.95 No lesions seen
B8 s2905.95 No lesions seen
B9 s2906.95 No lesions seen
Bl0 s2907.95 No lesions seen
Cl s2908.95 Mild multifocal steatitis of the mesenteric fat; No other lesions seen
C2 s2909.95 No lesions seen
C3 s2910.95 No lesions seen
C4 s2911.95 No lesions seen
C5 s2912.95 No lesions seen
C6 s2913.95 No lesions seen
C7 s2914.95 Mild diffuse tubular epithelial haemosiderosis; liver contains scattered Kupffer cell s
containing large aggregates of lipofuscin. The lesions in the kidney reflect prior systemic
haemolysis; No other lesions seen
C8 ~2915.95 No lesions seen
C9 s2916.95 No lesions seen
Cl0 s2917.95 Mild hepatocellular atrophy; No other lesions seen
The lesions seen in the individual animals are considered to be very mild and are likely to be non-
specific; there was no pattern seen in the various groups nor were there consistent changes within
groups
APPENDIX III
Ref.: UDW EC No. 94150
Universiteit van Pretoria
Privaalaak X04 Ondel3t8poort 0110 Republlek van Suid-Alrika









HISTOLOGICAL ASSESSMENT OF TISSUE SAMPLES
The following are the results of rat organ samples (liver, kidney and pancreas) of 21 September 1995,
ref. 94150 (22 November 1995) and 94150 (14 February 1996). The organs were examined blind (not
hCiving knowledge of treatment, not which were control or treatment groups. The results are for
interpretation by the investigator
Should you require photomicrographs of the lesions seen in the various animals, I shall be happy to
preduce them for you
I will be happy to discuss these findings as they cannot be interpreted further without other relevant
information
I trust that you will find these results to be of some value
Yours sincerely
N P J KRIEK
PROF AND HEAD: DEPARTMENT OF PATHOLOGY
21 September 1995:
Ref no. Histo no. Remarks
xx1 s2610.95 Mild multifocal pancreatic atrophy and fibrosis; No cthe .. lesions seen
yy1 s2611.95 Moderate multifocal granulomatous st6atitis in m6senetric fat; No other lesions se6n
zz1 s2612.95 Mild multifocal exocrine pancreatic hypertrophy; No other lesions se6n
xx2 s2613.95 Moderate multifocal granulomatous steatitis in mesenetric fat; No other lesions seen
zz2 52614.95 No lesions seen
xx3 s2615.95 Mild anisonucleosis in the hepatocytes; mild diffuse nephrosis characterized mostly by
mild to moderate cell swelling; mild renal tubular dilatation; No other lesions seen
yy3 s2616.95 Mild to moderate anisonucleosis and 'mild hepatoc611ular atrophy; Moderate multifocal
granulomatous steatitis in mesenetric fat; mild renal tubular dilatation; No other lesions
seen
xx4 s2617.95 No lesions seen
yy4 s2618.95 Lesions masked by advanced autolysis; severe congestion of all the tissues; mild
anisonucleosis of the hepatocytes
zz4 s2619.95 Mild multifocal granulomatous steatitis .in mesenetric fat; No other lesions seen
xx5 s2620.95 No lesions seen
yy5 s2621.95 Mild focal pancreatic atrophy and fibrosis (singl6 focus); No other 16sions S6en
zz5 s2622.95 No lesions seen
xx6 s2623.95 No lesions seen
yy6 s2624.95 No lesions seen
zz6 s2625.95 Mild hepatocellular atrophy; Mild'multifocal granulomatous steatitis in mesenetric fat; No
other lesions seen
xx7 s2626.95 Moderate hepatocellular atrophy; moderate multi focal granulomatous steatitis in
mesenetric fat; No other lesions seen
yy7 s2627.95 Mild multifocal granulomatous steatitis in mes6netric fat; No other lesions seen
zz7 s2628.95 Mild multifocal granulomatous steatitis in mesenetric fat; No other lesions seen
xx8 s2629.95 No lesions seen
yy8 s2630.95 No lesions seen
zz8 s2631.95 Mild renal cortical tubular dilatation; mild hepatocellular atrophy; No other lesions seen
xx9 s2632.95 Mild multifocal cortical rubular dilatation; No other lesions seen
yy9 s2633.95 Mild multi focal cortical rubular dilatation; No other lesions seen
zz9 s2634.95 Mild multifocal cortical rubular dilatation; No other lesions seen
The lesions seen in these animals are very mild and mostly related to chamges in the kidneys and the
liver. The changes in the liver are limited to atrophy. The affected kidneys manifested varying degrees
of tubular dilatation on the cortex; in all instances there was no accumulated material in the tubules
but the epithelium manifested mild to severe atrophy of the epithelial cells. One would need access
to the details of the experimental design to fully interpret the significance of the changes
Ref no. Histo no. Remarks Mild multifocal granulomatous steatitis in mesenetric fat;
A1 s500.96 Mild hepatocellular atrophy; No other lesions seen
A2 s501.96 Moderate hepatocellular atrophy; scant variation in hepatocellular nuclear size
(anisonucleosisl; scant hepatocellula~ fatty changes; moderate autolytic changes in the
kidney and pancreas
A3 s502.96 No lesions seen
A4 s503.96 Moderate multi focal granulomatous steatitis of mesenteric fat (amorphous particulate
matter present in some of the foci; No other lesions seen
A5 s504.96 Moderate multifocal granulomatous steatitis of mesenteric fat (amorphous particulate
matter present in some of the foci; mild hepatocellular atrophy and cell swelling;
A6 s505.96 Moderate multifocal granulomatous steatitis of mesenteric fat (amorphous particulate
matter present in some of the foci; mild hepatocellular atrophy end cell swelling;
A9 s506.96 Mild focal nodular pancreatic hyperplasia (exocrine); moderate multifocal renal cortical
scarring with multifocal tubular atrophy and marked focal increase in nuclear size,
clustering of nuclear and pronounced nuclear atypia; scattered small aggregates of
haemosiderin and lipofuscin occur in these areas; mild hepatocellular anisonucleosis; No
other lesions seen
63 s507.96 Mild hepatocellular atrophy; No other lesions seen
64 s508.96 Mild hepatocellular atrophy; No other lesions seen
65 s509.96 Severe renal lesions characterized by hyaline casts, multifocal severe renal tubular atrophy
and mild dilatation. In all these areas there is severe nuclear atypia characterized by
increased nuclear size, irregular outline, large single nucleoli and piling·up of nuclei in
certain of the areas. Aggregates of lipofuscin occur in macrophages in these areas in
addition to a scant multifocal lymphocytic infiltrate. In the remaining normal renal tubules
few cell s are necrotic and being cast off into the lumen
67 s510.96 Mild hepatocellular atrophy; mild diffuse renal haemosiderosis; No other lesions seen
68 s511.96 Moderate hepatocellular atrophy; lesions in the kidney cortex as for 65, though the cellular
atypia is not as advanced
69 s512.96 Mild hepatocellular atrophy; mild multifocal exocrine pancreatic hyperplasia; mild diffuse
renal haemosiderosis; No other lesions seen
610 s513.96 Moderate hepatocellular atrophy; No other lesions seen
C2 s514.96 No lesions seen
C3 s515.96 No lesior"ls seen
C4 s516.96 Mild hepatocellular atrophy; No other lesions seen
C5 s517.96 No lesions seen
C8 s518.96 Moderate multifocal pancreatic exocrine hyperplasia; mild focal steatitis; no other lesions
seen
C9 s519.96 No lesions seen
14 February 1996 {The organs were examined blind (not having knowledge of treatment, not which
were control or treatment groups The results are for interpretation by the investigator)
The lesions seen in a number of these animals, particularly those in ti:le kidney, and to a lesser extent
in the liver, are considered to be of significance. The lesions reflect chronic changes induced most
likely by some or other toxin that also has a marked effect on nuclear growth and development The
changes seen in the renal nuclei reflect those seen in pre-neoplastic lesions. It is suggested that these
lesions may progress (to neoplasia 7) in experiments of longer duration
It may be that some of the mild lesions seen in the kidneys in the animals in the earlier groups, may





Name of the interviewer
Briefly what the study is all about
1. Name: _
3, Yrs in Practice: -----
2. Name of the place: _
4. Previous address: --------
5. Any referrals from other places? : _
6. List the diseases which you treat _
7. Do you specialise in treating any disease? If yes, specify --------
8. Have you ever treated sugar diabetes before?
--------------
9. How do you diagnose it?
-------'----"""7"""-------------
10. May I talk to SOme of the patients that you have treated?-------
11. How do you treat it. _
12. Do you mind telling us what goes into the preparation: the plants used, whether it's a root,
bark, leaves,flowers or seeds
13. Are there particular times during the day or season that these are collected and why?
14. Are there any other additional ingredients added?
15. How is this (mixture) prepared?
16. How is this (medication) taken (dose);
b) how often and
c) for how long?
17. How frequent (in the last month) do you encounter patients who have been to the hospital or
doctor and feel they did not get the help they needed and they want YOU to treat
them?--------------------------
18. What is your opinion regarding allopathic medicine as opposed to traditional healing?
19. If you have problems treating certain ailments or cannot diagnose what is wrong with the
patient, do you refer them to a) other Traditional Healer or
b) biomedical practitioners?
20. Is collaboration between ethnomedicine and biomedicine a feasible venture?
21. Do you have any suggestions how can this be achieved?







D D M M Y Y
1. Name Address & Phone: .
2. Hosp/Clinic No.




4. Sex (M = 1; F = 2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. I I
L-J
5. Do you work for money or goods at all?
.-----l
Yes = 1 i No = 2 ·............. I I
L-J
a. If yes, work address and phone # .
b. If no,





Unemployed (fit for work)
On an old age pension
r---l
Other, specify ············· I I
L-J






I I > 40km
7. How do you usually travel to clinic?
1. Walk 4. Bus or Taxi
2 . Taxi 5. Train
3. Bus 6. Private Transport
7. Other, specify
r---l
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. I I
L-J
8. What is your average transport cost of visiting the clinic?
r---l
1. RO 4. R5 - R9.99 I I
2 . <R2 5. R10 - R19.99 L-J
3. R2 - R4.99 6. R20 - R30
9. How long does it usually take to get to the clinic?
1. < 1 hr
2. 1 - 2 hr
3. > 2 - 3 hr
4. > 3 hr
n
L-J
10. About how much do you usually pay at the clinic?
R
11. From when you arrive at the clinic grounds, how long do you
usually wait before you are seen?
r---l
1. < ~ hr 4. > 2 - 3 hr I I
2. ~ - < 1 hr 5. > 3 - 4 hr L-J
3 . 1 - 2 hr 6 . > 4 hr
12. a. How long have you attended the diabetes clinic?
M M















What is the name of the traditional healer you see/saw
15. Have you ever used traditional medicine for treatment of this




16. If yes: Did you
traditional ealer?


























18. How often did you/are you taking this muti?
........ " " .. " ..
.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. " .. 0 ..
19. For how long have you been taking this muti?
.................................................... D ..
20. Did/Does it help? Did/Does your sugar goes down after taking it?
................................................................................................................................
21. Does/Did it make you feel better?
................................................................................................................................
.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
3
22. Do/Did you take this together with the medication you got from the
hospital/doctor/clinic?




23. Do you think your sugar is controlled because of this traditional
muti?
24. a. What usually makes you go to the diabetic clinic?
b. You might have other reasons for going to the clinic.
Do you go to the clinic when?
1. You are ill
2. You have an
appointment
3. You have no
medication left




25. What makes it difficult for you to attend the clinic?
....................................................................................................................




Getting time off work
Wait{;g times at clinic
Other specify ............................................................................
4
27. Does your health make it difficult for you to do any work, chores
around the house or walk for a distance?
..............................................................................................................................
.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 0 - ..









29. What is diabetes?
(1 = correct; 2 = incorrect; 3 = don't know)
30. Do you know when your sugar is too low?
(1 = yes; 2 = no; 3 = don't know)
31. If yes, how can you tell?
b. Are you using 1. Diet
32. What do you when your sugar is low? .
.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .... .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..








:4. How do you know if your sugar is alright? .
."..
5
35. a. Do you e"'ver check your own sugar? 1 = yes; 2 = no
r-r
L-..J




















1. Patient Name: 2. ID:
3. Age 4. Approx DOB:
5. Sex 6. Weight
7. Height
8. Date of 1st Admission/Diagnosis:
9. Date of Discharge
10.Diagnosis
















15.1: Medication (type & dosage) : _
15.2: Insulin (type & dosage) : __~ __
15.3: Test Equipment:
11 11 Urine







CONSENT TO PARTICIPATE IN THE RESEARCH PROJECT
I, hereby give my consent to participate in the research
study
Mina, nginika imvume yokungenela lolucwaningo
where traditional remedies used in treating diabetes mellitus are investigated. I therefore promise that all the
lapho imithi yendalo esetshenziselwa ukwelapha isifo sikashukela izobe icwaningisiswa khona. Ngakhoke
the information that is given here is true and to my best knowledge is all that I know about this subject.
ngiyaqinisa ukuthi ngigeqe amagula olwazi lwami ngalesisifo nokwelashwa kwaso kusetshenziswa eyoMdabu.
I do this with understanding that this information will be kept secret and only be made available to the
Ngikwenza lokhu nginesiqiniseko sokuthi konke engikushoyo lapha kuzogcinwa esilulwini esaziwa
authorized research personnel and under no circumstances will it be divulged to pharmaceutical companies
abacwaningi abakhethiwe futhi alusobe Oolulwazi) ludluliselwe ezinkampanini ezakha irnithi namaphilisi
or any other researchers without prior agreement or permission from me.
ngaphandle kokuba sisayine isivumelwano esisha nalabacwaningi.
I, the undersigned, have agreed to participate voluntarily in this research
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